Harry Paul Erba | Scholars@Duke

Harry Paul Erba
Instructor in the Department of Medicine

I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine. I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies. I am also the Chair of the SWOG Leukemia Committee. I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.

Current Research Interests

I am a clinical investigator. I develop new therapies for people with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes and myeloproliferative neoplasms, including chronic myeloid leukemia. I have been the principal investigator for phase I, II and III studies.

Office Hours

Office hours:
Monday, 8 a.m. to 12 p.m.
Tuesday, 8 a.m. to 5 p.m.
Wednesday, 8 a.m. to 12 p.m.
Friday, 1 p.m. to 5 p.m.

Current Appointments & Affiliations

Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2018
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2018

Contact Information

2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
DUMC Box 3961, Durham, NC 27710
harry.erba@duke.edu (919) 668-1000
CV 080118
Erba Bio 080118
NIH Biosketch 080118

Background
Education, Training, & Certifications
- Research Fellowship in Medicine, Medicine, Harvard Medical School 1991 - 1993
- Research/Clinical Fellowship in Medicine, Medicine, Brigham and Women's Hospital 1991 - 1992
- Clinical Fellow in Medicine, Medicine, Harvard Medical School 1988 - 1991
- Residency Physician, Medicine, Brigham and Women's Hospital 1988 - 1990
- M.D., Stanford University School of Medicine 1988
- Ph.D., Stanford University 1988
Medical Licensure
- 2018-01322. North Carolina. 2018
- MD.31788. Alabama. 2012
Leadership & Clinical Positions at Duke
- Director, Leukemia Program, Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine
  Director, Phase I Development in Hematologic Malignancies
Academic Positions Outside Duke
- Chair, Leukemia Committee, SWOG. 2012 - 2022
Recognition
Awards & Honors
Expertise
Subject Headings
Global Scholarship
- Research
  - Alabama (State or Province)
  - Michigan (State or Province)
- Teaching
  - Alabama (State or Province)
  - Michigan (State or Province)
Research
Selected Grants
- DS3032-A-U105 awarded by Daiichi Sankyo Inc 2019 - 2024
- DS3201-A-U102 awarded by Daiichi Sankyo Inc 2018 - 2024
- GMI 1271 301 awarded by GlycoMimetics, Inc 2018 - 2023
- A phase 1, Multi-center, open-label study of IMGN632 administered intravenously in patients with relapsed/refractory CD123-positive acute myeloid leukemia and other CD123-positive hematologic mali awarded by ImmunoGen, Inc. 2018 - 2023
- SWOG Network Group Operations Center of the NCTN awarded by Oregon Health & Science University 2018 - 2019
Publications & Artistic Works
Selected Publications
- Academic Articles
  - LeBlanc, TW, and Erba, HP. "Shifting paradigms in the treatment of older adults with AML." Seminars in Hematology 56, no. 2 (April 2019): 110-117. (Review) Full Text
  - Stock, W, Luger, SM, Advani, AS, Yin, J, Harvey, RC, Mullighan, CG, Willman, CL, Fulton, N, Laumann, KM, Malnassy, G, Paietta, E, Parker, E, Geyer, S, Mrózek, K, Bloomfield, CD, Sanford, B, Marcucci, G, Liedtke, M, Claxton, DF, Foster, MC, Bogart, JA, Grecula, JC, Appelbaum, FR, Erba, H, Litzow, MR, Tallman, MS, Stone, RM, and Larson, RA. "A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403." Blood 133, no. 14 (April 2019): 1548-1559. Full Text
  - Medeiros, BC, Othus, M, Tallman, MS, Sun, Z, Fernandez, HF, Rowe, JM, Lazarus, HM, Appelbaum, FR, Luger, SM, Litzow, MR, and Erba, HP. "The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)." Leukemia Research 78 (March 2019): 29-33. Full Text
  - Othus, M, Estey, EH, Garcia-Manero, G, Wood, BL, Stirewalt, DL, Godwin, JE, Weick, JK, Anderson, JE, Appelbaum, FR, Erba, HP, and Walter, RB. "Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials." Leukemia 33, no. 2 (February 2019): 554-558. Full Text
  - Othus, M, Sekeres, MA, Nand, S, Garcia-Manero, G, Appelbaum, FR, Erba, HP, and Estey, E. "Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies." Leukemia 33, no. 2 (February 2019): 371-378. Full Text
  - Woyach, JA, Ruppert, AS, Heerema, NA, Zhao, W, Booth, AM, Ding, W, Bartlett, NL, Brander, DM, Barr, PM, Rogers, KA, Parikh, SA, Coutre, S, Hurria, A, Brown, JR, Lozanski, G, Blachly, JS, Ozer, HG, Major-Elechi, B, Fruth, B, Nattam, S, Larson, RA, Erba, H, Litzow, M, Owen, C, Kuzma, C, Abramson, JS, Little, RF, Smith, SE, Stone, RM, Mandrekar, SJ, and Byrd, JC. "Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL." The New England Journal of Medicine 379, no. 26 (December 2018): 2517-2528. Full Text
  - Halpern, AB, Othus, M, Huebner, EM, Scott, BL, Becker, PS, Percival, M-EM, Hendrie, PC, Gardner, KM, Chen, TL, Buckley, SA, Orlowski, KF, Anwar, A, Appelbaum, FR, Erba, HP, Estey, EH, and Walter, RB. "Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms." Leukemia 32, no. 11 (November 2018): 2352-2362. Full Text
  - Jamy, O, Bae, S, Costa, LJ, Erba, HP, and Papadantonakis, N. "Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow." Leukemia Research 74 (November 2018): 64-67. Full Text
  - Fathi, AT, Erba, HP, Lancet, JE, Stein, EM, Ravandi, F, Faderl, S, Walter, RB, Advani, AS, DeAngelo, DJ, Kovacsovics, TJ, Jillella, A, Bixby, D, Levy, MY, O'Meara, MM, Ho, PA, Voellinger, J, and Stein, AS. "A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML." Blood 132, no. 11 (September 2018): 1125-1133. Full Text
  - DiNardo, CD, Stein, EM, de Botton, S, Roboz, GJ, Altman, JK, Mims, AS, Swords, R, Collins, RH, Mannis, GN, Pollyea, DA, Donnellan, W, Fathi, AT, Pigneux, A, Erba, HP, Prince, GT, Stein, AS, Uy, GL, Foran, JM, Traer, E, Stuart, RK, Arellano, ML, Slack, JL, Sekeres, MA, Willekens, C, Choe, S, Wang, H, Zhang, V, Yen, KE, Kapsalis, SM, Yang, H, Dai, D, Fan, B, Goldwasser, M, Liu, H, Agresta, S, Wu, B, Attar, EC, Tallman, MS, Stone, RM, and Kantarjian, HM. "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML." The New England Journal of Medicine 378, no. 25 (June 2, 2018): 2386-2398. Full Text
  - Statler, A, Othus, M, Erba, HP, Chauncey, TR, Radich, JP, Coutre, S, Advani, A, Nand, S, Ravandi, F, Mukherjee, S, and Sekeres, MA. "Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies." Blood 131, no. 25 (June 2018): 2782-2788. Full Text
  - Stahl, M, Pine, A, Hendrickson, JE, Litzow, MR, Luger, SM, Stone, RM, Erba, HP, Kim, TK, Sekeres, MA, Steensma, DP, Komrokji, RS, Gore, SD, and Zeidan, AM. "Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey^* (Accepted)." Leukemia and Lymphoma (April 18, 2018): 1-4. Full Text
  - Advani, AS, Li, H, Michaelis, LC, Medeiros, BC, Liedtke, M, List, AF, O'Dwyer, K, Othus, M, Erba, HP, and Appelbaum, FR. "Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)." Leukemia Research 67 (April 2018): 17-20. Full Text
  - Swords, RT, Coutre, S, Maris, MB, Zeidner, JF, Foran, JM, Cruz, J, Erba, HP, Berdeja, JG, Tam, W, Vardhanabhuti, S, Pawlikowska-Dobler, I, Faessel, HM, Dash, AB, Sedarati, F, Dezube, BJ, Faller, DV, and Savona, MR. "Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML." Blood 131, no. 13 (March 2018): 1415-1424. Full Text
  - Pogosova-Agadjanyan, EL, Moseley, A, Othus, M, Appelbaum, FR, Chauncey, TR, Chen, I-ML, Erba, HP, Godwin, JE, Fang, M, Kopecky, KJ, List, AF, Pogosov, GL, Radich, JP, Willman, CL, Wood, BL, Meshinchi, S, and Stirewalt, DL. "Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report." Biopreservation and Biobanking 16, no. 1 (February 2018): 42-52. Full Text
  - Walter, RB, Michaelis, LC, Othus, M, Uy, GL, Radich, JP, Little, RF, Hita, S, Saini, L, Foran, JM, Gerds, AT, Klepin, HD, Hay, AE, Assouline, S, Lancet, JE, Couban, S, Litzow, MR, Stone, RM, and Erba, HP. "Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia." American Journal of Hematology 93, no. 2 (February 2018): E49-E52. (Letter) Full Text
  - Stein, EM, Walter, RB, Erba, HP, Fathi, AT, Advani, AS, Lancet, JE, Ravandi, F, Kovacsovics, T, DeAngelo, DJ, Bixby, D, Faderl, S, Jillella, AP, Ho, PA, O'Meara, MM, Zhao, B, Biddle-Snead, C, and Stein, AS. "A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia." Blood 131, no. 4 (January 2018): 387-396. Full Text
  - Perl, AE, Altman, JK, Cortes, J, Smith, C, Litzow, M, Baer, MR, Claxton, D, Erba, HP, Gill, S, Goldberg, S, Jurcic, JG, Larson, RA, Liu, C, Ritchie, E, Schiller, G, Spira, AI, Strickland, SA, Tibes, R, Ustun, C, Wang, ES, Stuart, R, Röllig, C, Neubauer, A, Martinelli, G, Bahceci, E, and Levis, M. "Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study." The Lancet. Oncology 18, no. 8 (August 2017): 1061-1075. Full Text
  - Qu, X, Othus, M, Davison, J, Wu, Y, Yan, L, Meshinchi, S, Ostronoff, F, Estey, EH, Radich, JP, Erba, HP, Appelbaum, FR, and Fang, M. "Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials." Cancer 123, no. 13 (July 2017): 2472-2481. Full Text
  - Mantha, S, Goldman, DA, Devlin, SM, Lee, J-W, Zannino, D, Collins, M, Douer, D, Iland, HJ, Litzow, MR, Stein, EM, Appelbaum, FR, Larson, RA, Stone, R, Powell, BL, Geyer, S, Laumann, K, Rowe, JM, Erba, H, Coutre, S, Othus, M, Park, JH, Wiernik, PH, and Tallman, MS. "Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era." Blood 129, no. 13 (March 30, 2017): 1763-1767. (Academic Article) Full Text Link to Item
  - Mantha, S, Goldman, DA, Devlin, SM, Lee, J-W, Zannino, D, Collins, M, Douer, D, Iland, HJ, Litzow, MR, Stein, EM, Appelbaum, FR, Larson, RA, Stone, R, Powell, BL, Geyer, S, Laumann, K, Rowe, JM, Erba, H, Coutre, S, Othus, M, Park, JH, Wiernik, PH, and Tallman, MS. "Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era." Blood 129, no. 13 (March 2017): 1763-1767. Full Text
  - Swords, RT, Watts, J, Erba, HP, Altman, JK, Maris, M, Anwer, F, Hua, Z, Stein, H, Faessel, H, Sedarati, F, Dezube, BJ, Giles, FJ, Medeiros, BC, and DeAngelo, DJ. "Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes." Blood Cancer Journal 7, no. 2 (February 3, 2017): e520-null. (Letter) Full Text
  - Moinpour, CM, Unger, JM, Ganz, PA, Kornblith, AB, Gaynor, ER, Bowers, MA, Gatti, GS, Kaminski, MS, Erba, HP, Wang, T, Yoon, J, Press, OW, and Fisher, RI. "Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208." Journal of Cancer Survivorship : Research and Practice 11, no. 1 (February 2017): 32-40. Full Text
  - Pine, AB, Lee, E-J, Sekeres, M, Steensma, DP, Zelterman, D, Prebet, T, DeZern, A, Komrokji, R, Litzow, M, Luger, S, Stone, R, Erba, HP, Garcia-Manero, G, Lee, AI, Podoltsev, NA, Barbarotta, L, Kasberg, S, Hendrickson, JE, Gore, SD, and Zeidan, AM. "Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States." Transfusion 57, no. 2 (February 2017): 289-295. Full Text
  - Minagawa, K, Jamil, MO, Al-Obaidi, M, Pereboeva, L, Salzman, D, Erba, HP, Lamb, LS, Bhatia, R, Mineishi, S, and Di Stasi, A. "Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia." Plos One 12, no. 2 (January 2017): e0172640-null. Full Text
  - Ravandi, F, Othus, M, O'Brien, SM, Forman, SJ, Ha, CS, Wong, JYC, Tallman, MS, Paietta, E, Racevskis, J, Uy, GL, Horowitz, M, Takebe, N, Little, R, Borate, U, Kebriaei, P, Kingsbury, L, Kantarjian, HM, Radich, JP, Erba, HP, and Appelbaum, FR. "US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL." Blood Advances 1, no. 3 (December 2016): 250-259. Full Text
  - Othus, M, Wood, BL, Stirewalt, DL, Estey, EH, Petersdorf, SH, Appelbaum, FR, Erba, HP, and Walter, RB. "Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia." Leukemia 30, no. 10 (October 2016): 2080-2083. (Letter) Full Text
  - Steensma, DP, Abedi, M, Bejar, R, Cogle, CR, Foucar, K, Garcia-Manero, G, George, TI, Grinblatt, D, Komrokji, R, Ma, X, Maciejewski, J, Pollyea, DA, Savona, MR, Scott, B, Sekeres, MA, Thompson, MA, Swern, AS, Nifenecker, M, Sugrue, MM, and Erba, H. "Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study." Bmc Cancer 16 (August 19, 2016): 652-null. Full Text
  - Othus, M, Mukherjee, S, Sekeres, MA, Godwin, J, Petersdorf, S, Appelbaum, FR, Erba, H, and Estey, E. "Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course." Leukemia 30, no. 8 (August 2016): 1779-1780. (Letter) Full Text
  - Othus, M, van Putten, W, Lowenberg, B, Petersdorf, SH, Nand, S, Erba, H, Appelbaum, F, Hills, R, Russell, N, Burnett, A, and Estey, E. "Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI." Haematologica 101, no. 7 (July 2016): e284-e286. (Letter) Full Text
  - Achille, NJ, Othus, M, Phelan, K, Zhang, S, Cooper, K, Godwin, JE, Appelbaum, FR, Radich, JP, Erba, HP, Nand, S, and Zeleznik-Le, NJ. "Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients." Leukemia research 42 (March 2016): 68-74. Full Text
  - Prebet, T, Sun, Z, Ketterling, RP, Zeidan, A, Greenberg, P, Herman, J, Juckett, M, Smith, MR, Malick, L, Paietta, E, Czader, M, Figueroa, M, Gabrilove, J, Erba, HP, Tallman, MS, Litzow, M, Gore, SD, and Eastern Cooperative Oncology Group and North American Leukemia intergroup, . "Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study." British Journal of Haematology 172, no. 3 (February 2016): 384-391. Full Text
  - Minagawa, K, Jamil, MO, Al-Obaidi, M, Pereboeva, L, Salzman, D, Erba, HP, Lamb, LS, Bhatia, R, Mineishi, S, and Di Stasi, A. "In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia." Plos One 11, no. 12 (January 2016): e0166891-null. Full Text
  - Walter, RB, Othus, M, Löwenberg, B, Ossenkoppele, GJ, Petersdorf, SH, Pabst, T, Vekemans, M-C, Appelbaum, FR, Erba, HP, and Estey, EH. "Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG." Haematologica 100, no. 10 (October 2015): e409-e411. (Letter) Full Text
  - Ravandi, F, Ritchie, EK, Sayar, H, Lancet, JE, Craig, MD, Vey, N, Strickland, SA, Schiller, GJ, Jabbour, E, Erba, HP, Pigneux, A, Horst, H-A, Recher, C, Klimek, VM, Cortes, J, Roboz, GJ, Odenike, O, Thomas, X, Havelange, V, Maertens, J, Derigs, H-G, Heuser, M, Damon, L, Powell, BL, Gaidano, G, Carella, A-M, Wei, A, Hogge, D, Craig, AR, Fox, JA, Ward, R, Smith, JA, Acton, G, Mehta, C, Stuart, RK, and Kantarjian, HM. "Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study." The Lancet. Oncology 16, no. 9 (September 2015): 1025-1036. Full Text
  - Tefferi, A, Kantarjian, H, Rajkumar, SV, Baker, LH, Abkowitz, JL, Adamson, JW, Advani, RH, Allison, J, Antman, KH, Bast, RC, Bennett, JM, Benz, EJ, Berliner, N, Bertino, J, Bhatia, R, Bhatia, S, Bhojwani, D, Blanke, CD, Bloomfield, CD, Bosserman, L, Broxmeyer, HE, Byrd, JC, Cabanillas, F, Canellos, GP, Chabner, BA, Chanan-Khan, A, Cheson, B, Clarkson, B, Cohn, SL, Colon-Otero, G, Cortes, J, Coutre, S, Cristofanilli, M, Curran, WJ, Daley, GQ, DeAngelo, DJ, Deeg, HJ, Einhorn, LH, Erba, HP, Esteva, FJ, Estey, E, Fidler, IJ, Foran, J, Forman, S, Freireich, E, Fuchs, C, George, JN, Gertz, MA, Giralt, S, Golomb, H, Greenberg, P, Gutterman, J, Handin, RI, Hellman, S, Hoff, PM, Hoffman, R, Hong, WK, Horowitz, M, Hortobagyi, GN, Hudis, C, Issa, JP, Johnson, BE, Kantoff, PW, Kaushansky, K, Khayat, D, Khuri, FR, Kipps, TJ, Kripke, M, Kyle, RA, Larson, RA, Lawrence, TS, Levine, R, Link, MP, Lippman, SM, Lonial, S, Lyman, GH, Markman, M, Mendelsohn, J, Meropol, NJ, Messinger, Y, Mulvey, TM, O'Brien, S, Perez-Soler, R, Pollock, R, Prchal, J, Press, O, Radich, J, Rai, K, Rosenberg, SA, Rowe, JM, Rugo, H, Runowicz, CD, Sandmaier, BM, Saven, A, Schafer, AI, Schiffer, C, Sekeres, MA, Silver, RT, Siu, LL, Steensma, DP, Stewart, FM, Stock, W, Stone, R, Storb, R, Strong, LC, Tallman, MS, Thompson, M, Ueno, NT, Van Etten, RA, Vose, JM, Wiernik, PH, Winer, EP, Younes, A, Zelenetz, AD, and LeMaistre, CA. "In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs." Mayo Clinic Proceedings 90, no. 8 (August 2015): 996-1000. Full Text
  - DiPersio, JF, Erba, HP, Larson, RA, Luger, SM, Tallman, MS, Brill, JM, Vuagniaux, G, Rouits, E, Sorensen, JM, and Zanna, C. "Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study." Clinical lymphoma, myeloma & leukemia 15, no. 7 (July 2015): 443-449. Full Text
  - Swords, RT, Erba, HP, DeAngelo, DJ, Bixby, DL, Altman, JK, Maris, M, Hua, Z, Blakemore, SJ, Faessel, H, Sedarati, F, Dezube, BJ, Giles, FJ, and Medeiros, BC. "Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study." British Journal of Haematology 169, no. 4 (May 2015): 534-543. Full Text
  - Stone, RM, Mazzola, E, Neuberg, D, Allen, SL, Pigneux, A, Stuart, RK, Wetzler, M, Rizzieri, D, Erba, HP, Damon, L, Jang, J-H, Tallman, MS, Warzocha, K, Masszi, T, Sekeres, MA, Egyed, M, Horst, H-A, Selleslag, D, Solomon, SR, Venugopal, P, Lundberg, AS, and Powell, B. "Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 11 (April 2015): 1252-1257. Full Text
  - Erba, HP. "Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission." American journal of hematology 90, no. 3 (March 2015): 242-249. (Review) Full Text
  - Medeiros, BC, Othus, M, Fang, M, Appelbaum, FR, and Erba, HP. "Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia." Haematologica 100, no. 3 (March 2015): 331-335. Full Text
  - Michaelis, LC, and Erba, HP. "Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014." Current opinion in hematology 22, no. 2 (March 2015): 108-115. (Review) Full Text
  - Othus, M, Appelbaum, FR, Petersdorf, SH, Kopecky, KJ, Slovak, M, Nevill, T, Brandwein, J, Larson, RA, Stiff, PJ, Walter, RB, Tallman, MS, Stenke, L, and Erba, HP. "Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 21, no. 3 (March 2015): 559-564. Full Text
  - Erba, HP. "Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy." Leukemia Research 39, no. 2 (February 2015): 183-191. (Review) Full Text
  - Lindsley, RC, Mar, BG, Mazzola, E, Grauman, PV, Shareef, S, Allen, SL, Pigneux, A, Wetzler, M, Stuart, RK, Erba, HP, Damon, LE, Powell, BL, Lindeman, N, Steensma, DP, Wadleigh, M, DeAngelo, DJ, Neuberg, D, Stone, RM, and Ebert, BL. "Acute myeloid leukemia ontogeny is defined by distinct somatic mutations." Blood 125, no. 9 (February 2015): 1367-1376. Full Text
  - Zeidan, AM, Lee, J-W, Prebet, T, Greenberg, P, Sun, Z, Juckett, M, Smith, MR, Paietta, E, Gabrilove, J, Erba, HP, Katterling, RP, Tallman, MS, and Gore, SD. "Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS." British journal of haematology 167, no. 1 (October 2014): 62-68. Full Text
  - Zeidan, AM, Lee, J-W, Prebet, T, Greenberg, P, Sun, Z, Juckett, M, Smith, MR, Paietta, E, Gabrilove, J, Erba, HP, Tallman, MS, Gore, SD, and Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup, . "Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes." British journal of haematology 166, no. 3 (August 2014): 352-359. Full Text
  - Prebet, T, Sun, Z, Figueroa, ME, Ketterling, R, Melnick, A, Greenberg, PL, Herman, J, Juckett, M, Smith, MR, Malick, L, Paietta, E, Czader, M, Litzow, M, Gabrilove, J, Erba, HP, Gore, SD, and Tallman, MS. "Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 12 (April 2014): 1242-1248. Full Text
  - Erba, HP, Othus, M, Walter, RB, Kirschbaum, MH, Tallman, MS, Larson, RA, Slovak, ML, Kopecky, KJ, Gundacker, HM, and Appelbaum, FR. "Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432." Leukemia Research 38, no. 3 (March 2014): 329-333. Full Text
  - Othus, M, Kantarjian, H, Petersdorf, S, Ravandi, F, Godwin, J, Cortes, J, Pierce, S, Erba, H, Faderl, S, Appelbaum, FR, and Estey, E. "Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson." Leukemia 28, no. 2 (February 2014): 289-292. Full Text
  - Jain, N, Curran, E, Iyengar, NM, Diaz-Flores, E, Kunnavakkam, R, Popplewell, L, Kirschbaum, MH, Karrison, T, Erba, HP, Green, M, Poire, X, Koval, G, Shannon, K, Reddy, PL, Joseph, L, Atallah, EL, Dy, P, Thomas, SP, Smith, SE, Doyle, LA, Stadler, WM, Larson, RA, Stock, W, and Odenike, O. "Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 20, no. 2 (January 2014): 490-498. Full Text
  - Schimmer, AD, Raza, A, Carter, TH, Claxton, D, Erba, H, DeAngelo, DJ, Tallman, MS, Goard, C, and Borthakur, G. "A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia." Plos One 9, no. 10 (January 2014): e108694-null. Full Text
  - Nand, S, Othus, M, Godwin, JE, Willman, CL, Norwood, TH, Howard, DS, Coutre, SE, Erba, HP, and Appelbaum, FR. "A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia." Blood 122, no. 20 (November 2013): 3432-3439. Full Text
  - Ravandi, F, Erba, HP, and Pollyea, DA. "Expert insights into the contemporary management of older adults with acute myeloid leukemia." Cancer control : journal of the Moffitt Cancer Center 20, no. 4 Suppl (October 2013): 5-16. Full Text
  - Erba, HP, Sayar, H, Juckett, M, Lahn, M, Andre, V, Callies, S, Schmidt, S, Kadam, S, Brandt, JT, Van Bockstaele, D, and Andreeff, M. "Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)." Investigational New Drugs 31, no. 4 (August 2013): 1023-1034. Full Text
  - Petersdorf, SH, Kopecky, KJ, Slovak, M, Willman, C, Nevill, T, Brandwein, J, Larson, RA, Erba, HP, Stiff, PJ, Stuart, RK, Walter, RB, Tallman, MS, Stenke, L, and Appelbaum, FR. "A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia." Blood 121, no. 24 (June 2013): 4854-4860. Full Text
  - Roth, BJ, Krilov, L, Adams, S, Aghajanian, CA, Bach, P, Braiteh, F, Brose, MS, Ellis, LM, Erba, H, George, DJ, Gilbert, MR, Jacobson, JO, Larsen, EC, Lichtman, SM, Partridge, AH, Patel, JD, Quinn, DI, Robison, LL, von Roenn, JH, Samlowski, W, Schwartz, GK, and Vogelzang, NJ. "Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 1 (January 2013): 131-161. Full Text
  - Borate, U, Absher, D, Erba, HP, and Pasche, B. "Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML." Expert Review of Anticancer Therapy 12, no. 10 (October 2012): 1289-1297. Full Text
  - Claxton, D, Erba, HP, Faderl, S, Arellano, M, Lyons, RM, Kovacsovics, T, Gabrilove, J, Huebner, D, Gandhi, PJ, Kantarjian, H, and CLASSIC II Investigators, . "Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia." Leukemia & Lymphoma 53, no. 3 (March 2012): 435-440. Full Text
  - Li, M, Collins, R, Jiao, Y, Ouillette, P, Bixby, D, Erba, H, Vogelstein, B, Kinzler, KW, Papadopoulos, N, and Malek, SN. "Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia." Blood 118, no. 22 (November 2011): 5914-5917. Full Text
  - Erba, HP, Pham, DC, Zaiden, R, Vu, H, and Tai, S. "Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib." Clinical advances in hematology & oncology : H&O 9, no. 10 (October 2011): 734-745. (Review)
  - Magenau, J, Tobai, H, Pawarode, A, Braun, T, Peres, E, Reddy, P, Kitko, C, Choi, S, Yanik, G, Frame, D, Harris, A, Erba, H, Kujawski, L, Elenitoba-Johnson, K, Sanks, J, Jones, D, Paczesny, S, Ferrara, J, Levine, J, and Mineishi, S. "Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies." Blood 118, no. 15 (October 2011): 4258-4264. Full Text
  - Saiya-Cork, K, Collins, R, Parkin, B, Ouillette, P, Kuizon, E, Kujawski, L, Erba, H, Campagnaro, E, Shedden, K, Kaminski, M, and Malek, SN. "A pathobiological role of the insulin receptor in chronic lymphocytic leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research 17, no. 9 (May 2011): 2679-2692. Full Text
  - Levis, M, Ravandi, F, Wang, ES, Baer, MR, Perl, A, Coutre, S, Erba, H, Stuart, RK, Baccarani, M, Cripe, LD, Tallman, MS, Meloni, G, Godley, LA, Langston, AA, Amadori, S, Lewis, ID, Nagler, A, Stone, R, Yee, K, Advani, A, Douer, D, Wiktor-Jedrzejczak, W, Juliusson, G, Litzow, MR, Petersdorf, S, Sanz, M, Kantarjian, HM, Sato, T, Tremmel, L, Bensen-Kennedy, DM, Small, D, and Smith, BD. "Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse." Blood 117, no. 12 (March 2011): 3294-3301. Full Text
  - Sekeres, MA, Maciejewski, JP, Erba, HP, Afable, M, Englehaupt, R, Sobecks, R, Advani, A, Seel, S, Chan, J, and Kalaycio, ME. "A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia." Cancer 117, no. 6 (March 2011): 1253-1261. Full Text
  - Wang, M, Medeiros, BC, Erba, HP, DeAngelo, DJ, Giles, FJ, and Swords, RT. "Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer." Expert opinion on therapeutic targets 15, no. 3 (March 2011): 253-264. (Review) Full Text
  - Erba, HP. "Has there been progress in the treatment of older patients with acute myeloid leukemia?." Best practice & research. Clinical haematology 23, no. 4 (December 2010): 495-501. (Review) Full Text
  - Parkin, B, Erba, H, Ouillette, P, Roulston, D, Purkayastha, A, Karp, J, Talpaz, M, Kujawski, L, Shakhan, S, Li, C, Shedden, K, and Malek, SN. "Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia." Blood 116, no. 23 (December 2010): 4958-4967. Full Text
  - Parkin, B, Ouillette, P, Wang, Y, Liu, Y, Wright, W, Roulston, D, Purkayastha, A, Dressel, A, Karp, J, Bockenstedt, P, Al-Zoubi, A, Talpaz, M, Kujawski, L, Liu, Y, Shedden, K, Shakhan, S, Li, C, Erba, H, and Malek, SN. "NF1 inactivation in adult acute myelogenous leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research 16, no. 16 (August 2010): 4135-4147. Full Text
  - Long, J, Parkin, B, Ouillette, P, Bixby, D, Shedden, K, Erba, H, Wang, S, and Malek, SN. "Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia." Blood 116, no. 1 (July 2010): 71-80. Full Text
  - Kantarjian, HM, Erba, HP, Claxton, D, Arellano, M, Lyons, RM, Kovascovics, T, Gabrilove, J, Craig, M, Douer, D, Maris, M, Petersdorf, S, Shami, PJ, Yeager, AM, Eckert, S, Abichandani, R, and Faderl, S. "Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 4 (February 2010): 549-555. Full Text
  - Chauncey, TR, Gundacker, H, Shadman, M, List, AF, Dakhil, SR, Erba, HP, Slovak, ML, Chen, I-M, Willman, CL, Kopecky, KJ, and Appelbaum, FR. "Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia." British Journal of Haematology 148, no. 1 (January 2010): 48-58. Full Text
  - O'Brien, S, Berman, E, Borghaei, H, Deangelo, DJ, Devetten, MP, Devine, S, Erba, HP, Gotlib, J, Jagasia, M, Moore, JO, Mughal, T, Pinilla-Ibarz, J, Radich, JP, Shah Md, NP, Shami, PJ, Smith, BD, Snyder, DS, Tallman, MS, Talpaz, M, Wetzler, M, and National Comprehensive Cancer Network, . "NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia." Journal of the National Comprehensive Cancer Network : JNCCN 7, no. 9 (October 2009): 984-1023. Full Text
  - Radich, JP, Zelenetz, AD, Chan, WC, Croce, CM, Czuczman, MS, Erba, HP, Horning, SJ, Houldsworth, J, Smith, BD, Snyder, DS, Sundar, HM, Wetzler, M, and Winter, JN. "NCCN task force report: molecular markers in leukemias and lymphomas." Journal of the National Comprehensive Cancer Network : JNCCN 7 Suppl 4 (July 2009): S1-34. (Review) Full Text
  - Crawford, J, Armitage, J, Balducci, L, Bennett, C, Blayney, DW, Cataland, SR, Dale, DC, Demetri, GD, Erba, HP, Foran, J, Freifeld, AG, Goemann, M, Heaney, ML, Htoy, S, Hudock, S, Kloth, DD, Kuter, DJ, Lyman, GH, Michaud, LB, Miyata, SC, Tallman, MS, Vadhan-Raj, S, Westervelt, P, Wong, MK, and National Comprehensive Cancer Network, . "Myeloid growth factors." Journal of the National Comprehensive Cancer Network : JNCCN 7, no. 1 (January 2009): 64-83. Full Text
  - Allen, SL, Erba, HP, Rizzieri, DA, O'Donnell, M, Powell, B, Lundberg, AS, Bennett, JM, and Capizzi, RL. "Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML." BLOOD 112, no. 11 (November 16, 2008): 1019-1020. Link to Item
  - O'Donnell, MR, Appelbaum, FR, Coutre, SE, Damon, LE, Erba, HP, Foran, J, Lancet, J, Maness, LJ, Marcucci, G, Maslak, PG, Millenson, M, Moore, JO, Ravandi, F, Schuening, F, Shami, P, Smith, BD, Stone, RM, Tallman, MS, Wang, E, and White, FL. "Acute myeloid leukemia." Journal of the National Comprehensive Cancer Network : JNCCN 6, no. 10 (November 2008): 962-993. (Review) Full Text
  - Greenberg, PL, Attar, E, Battiwalla, M, Bennett, JM, Bloomfield, CD, DeCastro, CM, Deeg, HJ, Erba, HP, Foran, JM, Garcia-Manero, G, Gore, SD, Head, D, Maness, LJ, Millenson, M, Nimer, SD, O'Donnell, MR, Saba, HI, Shami, PJ, Spiers, K, Stone, RM, Tallman, MS, Westervelt, P, and NCCN Myelodysplastic Syndromes Panel, . "Myelodysplastic syndromes." Journal of the National Comprehensive Cancer Network : JNCCN 6, no. 9 (October 2008): 902-926. Full Text
  - Kujawski, L, Ouillette, P, Erba, H, Saddler, C, Jakubowiak, A, Kaminski, M, Shedden, K, and Malek, SN. "Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia." Blood 112, no. 5 (September 2008): 1993-2003. Full Text
  - Rizzieri, DA, Erba, HP, O'Donnell, M, Powell, BL, Lundberg, AS, Bennett, JM, and Capizzi, RL. "Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations." Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 7027-7027. Full Text
  - Ouillette, P, Erba, H, Kujawski, L, Kaminski, M, Shedden, K, and Malek, SN. "Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14." Cancer Research 68, no. 4 (February 2008): 1012-1021. Full Text
  - Saddler, C, Ouillette, P, Kujawski, L, Shangary, S, Talpaz, M, Kaminski, M, Erba, H, Shedden, K, Wang, S, and Malek, SN. "Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia." Blood 111, no. 3 (February 2008): 1584-1593. Full Text
  - Greineder, CF, Nelson, PW, Dressel, AL, Erba, HP, and Younger, JG. "In vitro and in silico analysis of annexin V binding to lymphocytes as a biomarker in emergency department sepsis studies." Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine 14, no. 9 (September 2007): 763-771. Full Text
  - Shehab, N, DePestel, DD, Mackler, ER, Collins, CD, Welch, K, and Erba, HP. "Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia." Pharmacotherapy 27, no. 7 (July 2007): 970-979. Full Text
  - O'Brien, S, Berman, E, Bhalla, K, Copelan, EA, Devetten, MP, Emanuel, PD, Erba, HP, Greenberg, PL, Moore, JO, Przepiorka, D, Radich, JP, Schilder, RJ, Shami, P, Smith, BD, Snyder, DS, Soiffer, RJ, Tallman, MS, Talpaz, M, Wetzler, M, and National Comprehensive Cancer Network, . "Chronic myelogenous leukemia." Journal of the National Comprehensive Cancer Network : JNCCN 5, no. 5 (May 2007): 474-496. Full Text
  - Crawford, J, Althaus, B, Armitage, J, Balducci, L, Bennett, C, Blayney, DW, Cataland, SR, Dale, DC, Demetri, GD, Erba, HP, Foran, J, Freifeld, AG, Heaney, ML, Htoy, S, Kloth, DD, Lyman, GH, Messersmith, WA, Michaud, LB, Miyata, SC, Robbins, A, Tallman, MS, Vadhan-Raj, S, Westervelt, P, Wong, MK, and National Comprehensive Cancer Network (NCCN), . "Myeloid growth factors. Clinical practice guidelines in oncology." Journal of the National Comprehensive Cancer Network : JNCCN 5, no. 2 (February 2007): 188-202. Full Text
  - Erba, HP. "Prognostic factors in elderly patients with AML and the implications for treatment." Hematology. American Society of Hematology. Education Program (January 2007): 420-428. (Review) Full Text
  - Greenberg, PL, Baer, MR, Bennett, JM, Bloomfield, CD, De Castro, CM, Deeg, HJ, Devetten, MP, Emanuel, PD, Erba, HP, Estey, E, Foran, J, Gore, SD, Millenson, M, Navarro, WH, Nimer, SD, O'Donnell, MR, Saba, HI, Spiers, K, Stone, RM, and Tallman, MS. "Myelodysplastic syndromes clinical practice guidelines in oncology." Journal of the National Comprehensive Cancer Network : JNCCN 4, no. 1 (January 2006): 58-77. Full Text
  - O'Donnell, MR, Appelbaum, FR, Baer, MR, Byrd, JC, Coutre, SE, Damon, LE, Erba, HP, Estey, E, Foran, J, Lancet, J, Maness, LJ, Maslak, PG, Millenson, M, Moore, JO, Przepiorka, D, Shami, P, Smith, BD, Stone, RM, and Tallman, MS. "Acute myeloid leukemia clinical practice guidelines in oncology." Journal of the National Comprehensive Cancer Network : JNCCN 4, no. 1 (January 2006): 16-36. Full Text
  - O'Brien, S, Berman, E, Bhalla, K, Copelan, EA, Devetten, MP, Emanuel, PD, Erba, HP, Greenberg, PL, Moore, JO, Przepiorka, D, Radich, JP, Schilder, RJ, Shami, P, Smith, BD, Snyder, DS, Soiffer, RJ, Tallman, MS, Talpaz, M, and Wetzler, M. "Chronic myelogenous leukemia." Journal of the National Comprehensive Cancer Network : JNCCN 3, no. 6 (November 2005): 732-755. Full Text
  - Erba, HP. "Treatment options for newly diagnosed patients with chronic lymphocytic leukemia." Current hematology reports 3, no. 1 (January 2004): 47-53. (Review)
  - Ganz, PA, Moinpour, CM, Pauler, DK, Kornblith, AB, Gaynor, ER, Balcerzak, SP, Gatti, GS, Erba, HP, McCoy, S, Press, OW, and Fisher, RI. "Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 21, no. 18 (September 2003): 3512-3519. Full Text
  - Erba, HP. "Recent progress in the treatment of myelodysplastic syndrome in adult patients." Current opinion in oncology 15, no. 1 (January 2003): 1-9. (Review) Full Text
  - Larson, RA, Boogaerts, M, Estey, E, Karanes, C, Stadtmauer, EA, Sievers, EL, Mineur, P, Bennett, JM, Berger, MS, Eten, CB, Munteanu, M, Loken, MR, Van Dongen, JJM, Bernstein, ID, Appelbaum, FR, and Mylotarg Study Group, . "Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)." Leukemia 16, no. 9 (September 2002): 1627-1636. Full Text
  - Appelbaum, FR, Baer, MR, Carabasi, MH, Coutre, SE, Erba, HP, Estey, E, Glenn, MJ, Kraut, EH, Maslak, P, Millenson, M, Miller, CB, Saba, HI, Stone, R, Tallman, MS, and National Comprehensive Cancer Network, . "NCCN Practice Guidelines for Acute Myelogenous Leukemia." Oncology (Williston Park, N.Y.) 14, no. 11A (November 2000): 53-61.
  - Berman, E, Clift, RA, Copelan, EA, Emanuel, PD, Erba, HP, Glenn, MJ, Greenberg, PL, Jones, RJ, O'Brien, S, Saba, HI, Schilder, R, Snyder, DS, Soiffer, RJ, Tallman, MS, Wetzler, M, Ravandi-Kashani, F, Kantarjian, H, Talpaz, M, and National Comprehensive Cancer Network, . "NCCN Practice Guidelines for Chronic Myelogenous Leukemia." Oncology (Williston Park, N.Y.) 14, no. 11A (November 2000): 229-240.
  - O'Donnell, MR, Appelbaum, FR, Baer, MR, Carabasi, MH, Coutre, SE, Erba, HP, Estey, E, Glenn, MJ, Kraut, EH, Maslak, P, Millenson, M, Miller, CB, Saba, HI, Stone, R, and Tallman, MS. "NCCN Practice Guidelines for acute myelogenous leukemia." Oncology New York 14, no. 11A (November 1, 2000): 53-61. (Academic Article) Link to Item
  - Talpaz, M, Berman, E, Clift, RA, Copelan, EA, Emanuel, PD, Erba, HP, Glenn, MJ, Greenberg, PL, Jones, RJ, O'Brien, S, Saba, HI, Schilder, R, Snyder, DS, Soiffer, RJ, Tallman, MS, Wetzler, M, Ravandi-Kashani, F, and Kantarjian, H. "NCCN Practice Guidelines for chronic myelogenous leukemia." Oncology New York 14, no. 11A (November 1, 2000): 229-240. (Academic Article) Link to Item
  - Paciocco, G, Bossone, E, Erba, H, and Rubenfire, M. "Reversible pulmonary hypertension in POEMS syndrome--another etiology of triggered pulmonary vasculopathy?." The Canadian journal of cardiology 16, no. 8 (August 2000): 1007-1012. (Review)
  - Taylor, A, Erba, HP, Muscat, GE, and Kedes, L. "Nucleotide sequence and expression of the human skeletal alpha-actin gene: evolution of functional regulatory domains." Genomics 3, no. 4 (November 1988): 323-336. Full Text
  - Erba, HP, Eddy, R, Shows, T, Kedes, L, and Gunning, P. "Structure, chromosome location, and expression of the human gamma-actin gene: differential evolution, location, and expression of the cytoskeletal beta- and gamma-actin genes." Molecular and Cellular Biology 8, no. 4 (April 1988): 1775-1789. Full Text
  - Ng, SY, Erba, H, Latter, G, Kedes, L, and Leavitt, J. "Modulation of microfilament protein composition by transfected cytoskeletal actin genes." Molecular and Cellular Biology 8, no. 4 (April 1988): 1790-1794. Full Text
  - Cross, GS, Wilson, C, Erba, HP, and Woodland, HR. "Cytoskeletal actin gene families of Xenopus borealis and Xenopus laevis." Journal of molecular evolution 27, no. 1 (January 1988): 17-28. Full Text
  - Erba, HP, Gunning, P, and Kedes, L. "Nucleotide sequence of the human gamma cytoskeletal actin mRNA: anomalous evolution of vertebrate non-muscle actin genes." Nucleic Acids Research 14, no. 13 (July 1986): 5275-5294. Full Text
  - Stephenson, EC, Erba, HP, and Gall, JG. "Histone gene clusters of the newt notophthalmus are separated by long tracts of satellite DNA." Cell 24, no. 3 (June 1981): 639-647. Full Text
  - Stephenson, EC, Erba, HP, and Gall, JG. "Characterization of a cloned histone gene cluster of the newt Notophthalamus viridescens." Nucleic acids research 9, no. 10 (May 1981): 2281-2295. Full Text
  - Gall, JG, Stephenson, EC, Erba, HP, Diaz, MO, and Barsacchi-Pilone, G. "Histone genes are located at the sphere loci of newt lampbrush chromosomes." Chromosoma 84, no. 2 (January 1981): 159-171. Full Text
  - Varley, JM, Macgregor, HC, and Erba, HP. "Satellite DNA is transcribed on lampbrush chromosomes." Nature 283, no. 5748 (February 1980): 686-688. Full Text
  - Varley, JM, Macgregor, HC, Nardi, I, Andrews, C, and Erba, HP. "Cytological evidence of transcription of highly repeated DNA sequences during the lampbrush stage in Triturus cristatus carnifex." Chromosoma 80, no. 3 (January 1980): 289-307. Full Text
- Book Sections
  - Borate, U, and Erba, HP. "Cytogenetics and Prognostic Models in Myelodysplastic Syndromes." In Cancer Consult: Expertise for Clinical Practice, 106-112. June 20, 2014. Full Text
- Conference Papers
  - DiNardo, CD, Stein, EM, de Botton, S, Roboz, GJ, Altman, JK, Mims, AS, Swords, R, Collins, RH, Mannis, GN, Pollyea, DA, Donnellan, W, Fathi, AT, Pigneux, A, Erba, HP, Prince, GT, Stein, AS, Uy, GL, Foran, JM, Traer, E, Stuart, RK, Arellano, ML, Slack, JL, Sekeres, MA, Willekens, C, Choe, S, Wang, H, Zhang, V, Yen, KE, Kapsalis, SM, Yang, H, Dai, D, Fan, B, Goldwasser, M, Liu, H, Agresta, S, Wu, B, Attar, EC, Tallman, MS, Stone, RM, and Kantarjian, HM. "Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study." : CIG MEDIA GROUP, LP, September 1, 2018. Full Text Link to Item
  - George, T, Foucar, K, Pollyea, D, Erba, H, Thompson, M, Roboz, G, Pagel, J, Cogle, C, Nifenecker, M, Swern, A, Kiselev, P, and Sugrue, M. "Antecedent Conformity of Diagnostic and Molecular Testing Patterns in Clinical Practice for Newly Diagnosed Acute Myeloid Leukemia With American Society of Hematology and College of American Pathologists Guidelines." 52nd Annual Meeting of American-Society-of-Clinical-Pathologists/ (ASCP)/Academy-of-Clinical-Laboratory-Physicians-and-Scientists (ACLPS). New Haven, CT. June 15, 2017 - June 17, 2017. OXFORD UNIV PRESS INC, January 1, 2018. Link to Item
  - Cortes, JE, Traer, E, Wang, ES, Erba, HP, Blum, W, Arana-Yi, C, Sloss, CM, Culm-Merdek, K, Towles, J, Zweidler-McKay, PA, and DeAngelo, DJ. "IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017. Link to Item
  - DiNardo, CD, De Botton, S, Stein, EM, Roboz, GJ, Mims, AS, Pollyea, DA, Swords, RT, Altman, JK, Collins, RH, Mannis, GN, Uy, GL, Donnellan, W, Pigneux, A, Fathi, AT, Stein, AS, Erba, HP, Prince, GT, Foran, JM, Traer, E, Stuart, RK, Arellano, ML, Slack, JL, Sekeres, MA, Yen, K, Kapsalis, SM, Liu, H, Goldwasser, M, Agresta, S, Attar, EC, Tallman, MS, Stone, RM, and Kantarjian, HM. "Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017. Link to Item
  - Foran, JM, Zhang, Y, Heckman, M, Luger, S, Hulshizer, C, Vargas, E, Litzow, MR, Altman, JK, Pratz, K, Mattison, R, Claxton, DF, Uy, GL, Erba, HP, Cherry, MA, Broun, ER, Powell, BL, Lazarus, HM, Rowe, JM, Paietta, E, Little, RF, Poynter, J, Tallman, MS, and Cerhan, JR. "Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017. Link to Item
  - Jamy, O, Bae, S, Costa, LJ, Erba, HP, and Papadantonakis, N. "Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017. Link to Item
  - Othus, M, Garcia-Manero, G, Godwin, J, Weick, JK, Anderson, JE, Stirewalt, D, Appelbaum, FR, Erba, HP, and Estey, EH. "Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017. Link to Item
  - Ritchie, EK, Catchatourian, R, Klisovic, RB, Pinilla-Ibarz, J, Deininger, MW, Erba, HP, Radich, JP, Savona, MR, Dautaj, I, Purkayastha, D, Habucky, K, and Mauro, MJ. "Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017. Link to Item
  - Stahl, M, Pine, A, Hendrickson, JE, Litzow, MR, Luger, S, Stone, RM, Erba, HP, Kim, TK, Sekeres, MA, Steensma, DP, Komrokji, RS, Gore, SD, and Zeidan, AM. "Beliefs and Patterns of Practice in the Management of Hyperleukocytosis and Leukostasis Among Health Care Providers for Patients with Acute Leukemia: A Large North American Web-Based Survey." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017. Link to Item
  - Schlenk, R, Dombret, H, Amadori, S, Montesinos, P, Levis, M, Sekeres, MA, Cortes, J, Perl, A, Zernovak, O, Mires, D, Ge, N, Zhang, H, Hanyok, J, Macintyre, S, Gokmen, S, Kobayashi, K, and Erba, H. "QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)." 42nd European-Society-for-Medical-Oncology Congress (ESMO). Madrid, SPAIN. September 8, 2017 - September 12, 2017. OXFORD UNIV PRESS, September 1, 2017. Link to Item
  - Sekeres, MA, Othus, M, List, AF, Odenike, O, Stone, RM, Gore, SD, Litzow, MR, Buckstein, R, Fang, M, Roulston, D, Bloomfield, CD, Moseley, A, Nazha, A, Zhang, Y, Velasco, MR, Gaur, R, Atallah, E, Attar, EC, Cook, EK, Cull, AH, Rauh, MJ, Appelbaum, FR, and Erba, HP. "Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117." August 2017. Full Text
  - Cortes, J, DeAngelo, D, Wang, E, Arana-Yi, C, Zweidler-McKay, P, Munteanu, M, Andreu-Vieyra, C, Erba, H, Blum, W, and Traer, E. "INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML." 22nd Congress of the European-Hematology-Association. Madrid, SPAIN. June 22, 2017 - June 25, 2017. FERRATA STORTI FOUNDATION, June 26, 2017. Link to Item
  - Lancet, JE, Rizzieri, D, Schiller, GJ, Stuart, RK, Kolitz, JE, Solomon, SR, Newell, LF, Erba, H, Uy, GL, Ryan, R, Chiarella, M, Louie, AC, and Cortes, JE. "OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY." 22nd Congress of the European-Hematology-Association. Madrid, SPAIN. June 22, 2017 - June 25, 2017. FERRATA STORTI FOUNDATION, June 26, 2017. Link to Item
  - Levy, MY, Stein, AS, Vasu, S, Maris, MB, Advani, AS, Fathi, AT, Faderl, S, Walter, RB, Smith, SE, Yang, J, Donnellan, WB, Wood, BL, Ravandi, F, Feldman, EJ, Voellinger, JL, and Erba, H. "A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA." 22nd Congress of the European-Hematology-Association. Madrid, SPAIN. June 22, 2017 - June 25, 2017. FERRATA STORTI FOUNDATION, June 26, 2017. Link to Item
  - Medeiros, BC, Hogge, D, Newell, LF, Bixby, DL, Solomon, SR, Strickland, SA, Lin, TL, Erba, H, Powell, BL, Podoltsev, N, Ryan, R, Chiarella, M, Louie, AC, and Lancet, JE. "OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA." 22nd Congress of the European-Hematology-Association. Madrid, SPAIN. June 22, 2017 - June 25, 2017. FERRATA STORTI FOUNDATION, June 26, 2017. Link to Item
  - Pollyea, D, George, T, Foucar, K, Erba, H, Thompson, M, Roboz, G, Landau, D, Pagel, J, Seiter, K, Cogle, C, Nifenecker, M, Swern, A, Kiselev, P, and Sugrue, M. "MOLECULAR GENETIC TESTING PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) ENROLLED IN THE CONNECT (R) MDS/AML DISEASE REGISTRY." 22nd Congress of the European-Hematology-Association. Madrid, SPAIN. June 22, 2017 - June 25, 2017. FERRATA STORTI FOUNDATION, June 26, 2017. Link to Item
  - Ravandi, , Stein, A, Erba, H, Lancet, J, Stein, E, Faderl, S, Walter, R, Advani, A, DeAngelo, D, Kovacsovics, T, Jillella, A, Bixby, D, Levy, M, O'Meara, M, Ho, P, and Fathi, A. "VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS: A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIAF." 22nd Congress of the European-Hematology-Association. Madrid, SPAIN. June 22, 2017 - June 25, 2017. FERRATA STORTI FOUNDATION, June 26, 2017. Link to Item
  - Erba, HP, Becker, PS, Shami, PJ, Grunwald, MR, Flesher, DL, Zhang, Y, Rasmussen, E, Henary, HA, and Wang, ES. "Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML)." : American Society of Clinical Oncology (ASCO), May 20, 2017. Full Text
  - Lancet, JE, Rizzieri, D, Schiller, GJ, Stuart, RK, Kolitz, JE, Solomon, SR, Newell, LF, Erba, HP, Uy, GL, Ryan, R, Chiarella, M, Louie, AC, and Cortes, JE. "Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study." : American Society of Clinical Oncology (ASCO), May 20, 2017. Full Text
  - Medeiros, BC, Hogge, D, Newell, LF, Bixby, DL, Solomon, SR, Strickland, SA, Lin, TL, Erba, HP, Powell, BL, Podoltsev, NA, Ryan, R, Chiarella, M, Louie, A, and Lancet, JE. "Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML)." : American Society of Clinical Oncology (ASCO), May 20, 2017. Full Text
  - Pollyea, DA, George, T, Foucar, KM, Erba, HP, Thompson, MA, Abedi, M, Roboz, GJ, Landau, D, Pagel, JM, Seiter, K, Cogle, CR, Nifenecker, M, Swern, AS, Kiselev, P, and Sugrue, MM. "Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry." : American Society of Clinical Oncology (ASCO), May 20, 2017. Full Text
  - George, TI, Erba, HP, Pollyea, DA, Abedi, M, Roboz, GJ, Thompson, MA, Fliss, A, Swern, AS, Nifenecker, M, Kiselev, P, Sugrue, MM, and Foucar, K. "CURRENT DIAGNOSIS PATTERNS FOR ACUTE MYELOID LEUKEMIA: CONCORDANCE BETWEEN CLINICAL PRACTICE (CONNECT (R) DISEASE REGISTRY) AND WHO 2008 RECOMMENDATIONS." 14th International Symposium on Myelodysplastic Syndromes (MDS). Valencia, SPAIN. May 3, 2017 - May 6, 2017. PERGAMON-ELSEVIER SCIENCE LTD, April 1, 2017. Link to Item
  - Siniard, R, Burczyk-Brown, JJ, Godby, K, Erba, H, and Marques, MB. "Downward Platelet Utilization Trends in Acute Leukemia." : Oxford University Press (OUP), March 1, 2017. Full Text
  - Walter, R, Erba, H, and Ravandi, F. "A Phase 1b Study of Vadastuximab Talirine (33A) in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)." SPRINGER, February 1, 2017. Link to Item
  - Advani, AS, Moseley, A, Liedtke, M, O'Donnell, M, Othus, M, Mims, MP, O'Dwyer, K, and Erba, HP. "A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+Acute Leukemia (SWOG 1312)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Bixby, DL, Stein, AS, Fathi, AT, Kovacsovics, TJ, Levy, MY, Erba, HP, Lancet, JE, Jillella, AP, Ravandi, F, Walter, RB, Stein, EM, Faderl, S, DeAngelo, DJ, Ho, P, O'Meara, MM, Voellinger, JL, and Advani, A. "Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Erba, HP, Levy, MY, Vasu, S, Stein, AS, Fathi, AT, Maris, MB, Advani, A, Faderl, S, Smith, SE, Wood, BL, Walter, RB, Yang, J, Donnellan, WB, Feldman, EJ, Voellinger, JL, and Ravandi, F. "A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Fathi, AT, Erba, HP, Lancet, JE, Stein, EM, Ravandi, F, Faderl, S, Walter, RB, Advani, A, DeAngelo, DJ, Kovacsovics, TJ, Jillella, AP, Bixby, DL, Levy, MY, O'Meara, MM, Ho, P, and Stein, AS. "Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Garcia-Manero, G, Othus, M, Pagel, JM, Radich, JP, Fang, M, Rizzieri, DA, Marcucci, G, Strickland, SA, Litzow, M, Savoie, ML, Medeiros, BC, Sekeres, MA, Lin, TL, Uy, GL, Powell, BL, Kolitz, JE, Larson, RA, Stone, RM, Claxton, DF, Essell, J, Luger, S, Mohan, SR, Moseley, A, Appelbaum, FR, and Erba, HP. "SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - George, TI, Erba, HP, Steensma, DP, Pollyea, DA, Abedi, M, Bejar, R, Cogle, CR, Garcia-Manero, G, Grinblatt, DL, Komrokji, RS, Maciejewski, JP, Revicki, D, Roboz, GJ, Savona, MR, Scott, BL, Sekeres, MA, Thompson, MA, Fliss, A, Swern, AS, Nifenecker, M, Kiselev, P, Sugrue, MM, and Foucar, K. "Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT (R) Myelodysplastic Syndromes (MDS) and AML Disease Registry." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Halpern, AB, Othus, M, Huebner, EM, Orlowski, KF, Scott, BL, Smith, HA, Becker, PS, Percival, M-EM, Hendrie, PC, Perdue, AM, Chen, TL, Buckley, SA, Erba, HP, Estey, EH, and Walter, RB. "A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Othus, M, Sekeres, MA, Nand, S, Garcia-Manero, G, Appelbaum, FR, Erba, HP, and Estey, EH. "Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Pagel, JM, Othus, M, Garcia-Manero, G, Fang, M, Radich, JP, Rizzieri, DA, Marcucci, G, Strickland, SA, Litzow, M, Savoie, ML, Spellman, SR, Confer, DL, Chell, J, Brown, M, Medeiros, BC, Sekeres, MA, Lin, TL, Uy, GL, Powell, BL, Kolitz, JE, Larson, RA, Stone, RM, Claxton, DF, Essell, J, Luger, S, Mohan, SR, Moseley, A, Erba, HP, and Appelbaum, FR. "Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Perl, AE, Altman, JK, Cortes, JE, Smith, CC, Litzow, M, Baer, MR, Claxton, DF, Erba, HP, Gill, SC, Goldberg, SL, Jurcic, JG, Larson, RA, Liu, C, Ritchie, EK, Schiller, GJ, Spira, AI, Strickland, SA, Tibes, R, Ustun, C, Wang, ES, Stuart, RK, Rollig, C, Neubauer, A, Martinelli, G, Bahceci, E, and Levis, MJ. "Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/ Refractory Acute Myeloid Leukemia (R/R AML)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Pogosova-Agadjanyan, EL, Moseley, A, Wood, BL, Appelbaum, FR, Chauncey, T, Chen, I-ML, Erba, HP, Godwin, JE, Fang, M, Kopecky, KJ, List, AF, Othus, M, Radich, JP, Willman, CL, Meshinchi, S, and Stirewalt, DL. "Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Ravandi, F, Ritchie, EK, Sayar, H, Lancet, JE, Craig, M, Vey, N, Strickland, SA, Schiller, GJ, Jabbour, EJ, Erba, HP, Pigneux, A, Horst, H-A, Recher, C, Klimek, VM, Cortes, JE, Roboz, GJ, Craig, AR, Ward, R, Smith, J, Kantarjian, HM, and Stuart, RK. "Durable Overall Survival Benefit in Patients >= 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Ritchie, EK, Catchatourian, R, Klisovic, RB, Pinilla-Ibarz, J, Deininger, MW, Erba, HP, Radich, JP, Savona, MR, Dautaj, I, Wolff, J, and Mauro, MJ. "ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Statler, A, Othus, M, Erba, HP, Chauncey, TR, Radich, JP, Coutre, SE, Advani, AS, Nand, S, Ravandi, F, Mukherjee, S, and Sekeres, MA. "Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Swords, RT, Coutre, S, Maris, MB, Zeidner, JF, Foran, JM, Cruz, JC, Erba, HP, Berdeja, JG, Tam, W, Vardhanabhuti, S, Dobler, I, Faessel, HM, Dash, AB, Sedarati, F, Dezube, BJ, and Savona, MR. "Results of a Clinical Study of Pevonedistat (Pev),a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Yang, J, Ravandi, F, Advani, A, Vasu, S, Walter, RB, Faderl, S, Stein, AS, Erba, HP, Fathi, AT, Donnellan, WB, Levy, MY, Smith, SE, Wood, BL, Feldman, EJ, Voellinger, JL, and Maris, MB. "A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016. Link to Item
  - Fathi, A, Erba, H, Lancet, J, Stein, E, Ravandi, F, Faderl, S, Walter, R, Advani, A, DeAngelo, D, Kovacsovics, T, Jillella, A, Bixby, D, Levy, M, O'Meara, M, Ho, P, and Stein, A. "SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML." 21st Congress of the European-Hematology-Association. Copenhagen, DENMARK. June 9, 2016 - June 12, 2016. FERRATA STORTI FOUNDATION, June 1, 2016. Link to Item
  - Lancet, J, Uy, G, Cortes, J, Newell, L, Lin, T, Ritchie, E, Strickland, S, Stuart, R, Hogge, D, Solomon, S, Stone, R, Bixby, D, Kolitz, J, Schiller, G, Wieduwilt, M, Rao, A, Rubenstein, S, Stock, W, Foster, M, Erba, H, Goldberg, S, Powell, B, Podoltsev, N, Atallah, E, Warlick, E, Yee, K, Pagel, J, Norkin, M, Barta, S, Sandhu, I, Frankfurt, O, Gautier, M, Larson, M, Seiter, K, Levy, M, Bergeron, J, Berdeja, J, Kropf, P, Shemanski, L, Ryan, D, Chiarella, M, Paulsen, K, Louie, A, and Medeiros, B. "CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH HIGH RISK AML MARKEDLY INCREASES THE RESPONSE RATE OVER 7+3 IN PATIENTS WITH FLT3 MUTATIONS." 21st Congress of the European-Hematology-Association. Copenhagen, DENMARK. June 9, 2016 - June 12, 2016. FERRATA STORTI FOUNDATION, June 1, 2016. Link to Item
  - Erba, HP, Levis, MJ, Sekeres, MA, Dombret, H, Amadori, S, Zernovak, O, Mires, DE, Ge, N, Hanyok, J, Macintyre, S, Gokmen, S, Gammon, G, and Schlenk, RF. "Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (N Dx) FLT3-ITD-positive acute myeloid leukemia (AML): the QuANTUM-First study." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 3, 2016 - June 7, 2016.: AMER SOC CLINICAL ONCOLOGY, May 20, 2016. Full Text Link to Item
  - Hathaway, AR, Peker, D, Jackson, BE, Kota, VK, Shah, BD, Zhang, L, Jillella, AP, Arellano, M, Heffner, LT, Erba, HP, and Borate, U. "Early Allogeneic Stem Cell Transplantation Appears to Improve Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review." : Elsevier BV, March 2016. Full Text
  - Stein, AS, Walter, RB, Advani, AS, Ho, PA, and Erba, HP. "SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML)." : Elsevier BV, March 2016. Full Text
  - Advani, AS, Li, H, Michaelis, LC, Medeiros, BC, Liedtke, M, List, AF, O'Dwyer, K, Othus, M, Erba, HP, and Appelbaum, FR. "Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Altman, JK, Perl, AE, Cortes, JE, Levis, MJ, Smith, CC, Litzow, MR, Baer, MR, Claxton, DF, Erba, HP, Gill, SC, Goldberg, SL, Jurcic, JG, Larson, RA, Lui, C, Ritchie, EK, Sargent, B, Schiller, GJ, Spira, AI, Strickland, SA, Tibes, R, Ustun, C, Wang, ES, Stuart, RK, Baldus, CD, Rollig, C, Neubauer, A, Martinelli, G, and Bahceci, E. "Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Borate, U, Hathaway, AR, Peker, D, Jackson, BE, Kota, VK, Shah, BD, Zhang, L, Jillella, A, Arellano, M, Heffner, LT, and Erba, HP. "Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Borate, U, Lohiya, V, Sherwood, G, Jackson, BE, and Erba, HP. "Impact of Available Therapies on Survival of Very Elderly Myelodysplastic Syndrome (MDS) Patients (Age above 75 yrs)." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Fathi, AT, Erba, HP, Lancet, JE, Stein, EM, Walter, RB, DeAngelo, DJ, Faderl, S, Jillella, AP, Ravandi, F, Advani, AS, Bixby, D, Kovacsovics, TJ, O'Meara, MM, Kennedy, DA, and Stein, AS. "SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Lancet, JE, Ravandi, F, Ritchie, EK, Sayar, H, Strickland, SA, Schiller, GJ, Vey, N, Erba, HP, Pigneux, A, Horst, H-A, Recher, C, Odenike, O, Carella, A-M, Selleslag, D, Kell, J, Krug, U, Page, L, DeVault, A, Hwang, S, Craig, AR, and Stuart, RK. "Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Ostronoff, F, Alonzo, TA, Othus, M, Kutny, MA, Gerbing, RB, Radich, JP, Erba, HP, Appelbaum, FR, Kolb, EA, Gamis, AS, Stirewalt, DL, and Meshinchi, S. "Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Othus, M, Wood, BL, Estey, EH, Petersdorf, S, Appelbaum, FR, Erba, HP, and Walter, RB. "Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Pine, AB, Lee, E-J, Sekeres, MA, Steensma, DP, Prebet, T, DeZern, AE, Komrokji, RS, Litzow, MR, Luger, S, Stone, RM, Erba, HP, Garcia-Manero, G, Lee, AI, Podoltsev, NA, Barbarotta, L, Hendrickson, JE, Gore, SD, and Zeidan, AM. "North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Qu, X, Othus, M, Davison, J, Yan, L, Estey, EH, Radich, J, Erba, HP, Appelbaum, FR, and Fang, M. "Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Ravandi, F, Othus, M, O'Brien, S, Forman, SJ, Ha, CS, Wong, JYC, Tallman, MS, Paietta, E, Racevskis, J, Uy, GL, Borate, U, Kebriaei, P, Kingsbury, L, Kantarjian, HM, Radich, JP, Erba, HP, and Appelbaum, FR. "Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Ritchie, EK, Catchatourian, R, Klisovic, RB, Deininger, MW, Erba, HP, Radich, JP, Savona, MR, Warsi, G, Paley, CS, Dautaj, I, Lin, FP, and Mauro, MJ. "Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Sekeres, MA, Othus, M, List, AF, Odenike, O, Stone, RM, Gore, SD, Litzow, MR, Buckstein, R, Fang, M, Roulston, D, Bloomfield, CD, Zhang, Y, Velasco, MR, Gaur, R, Atallah, E, Attar, EC, Appelbaum, FR, and Erba, HP. "Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Stein, AS, Walter, RB, Erba, HP, Fathi, AT, Advani, AS, Lancet, JE, Ravandi, F, Kovacsovics, TJ, DeAngelo, DJ, Bixby, D, Faderl, S, Jillella, AP, O'Meara, MM, Zhao, B, and Stein, EM. "A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)." 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 5, 2015 - December 8, 2015.: AMER SOC HEMATOLOGY, December 3, 2015. Link to Item
  - Carella, A-M, Ravandi, F, Ritchie, EK, Sayar, H, Lancet, JE, Craig, MD, Vey, N, Strickland, SA, Schiller, GJ, Jabbour, E, Erba, HP, Pigneux, A, Horst, H-A, Recher, C, Klimek, VM, Cortes, J, Roboz, GJ, Craig, AR, Fox, JA, Ward, R, Smith, JA, Acton, G, Mehta, C, Kantarjian, HM, and Stuart, RK. "IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY." 45th Congress of the Italian-Society-of-Hematology. Florence, ITALY. October 4, 2015 - October 7, 2015. FERRATA STORTI FOUNDATION, October 1, 2015. Link to Item
  - Krug, U, Ravandi, F, Ritchie, EK, Sayar, H, Lancet, JE, Craig, MD, Vey, N, Strickland, SA, Schiller, GJ, Jabbour, E, Erba, HP, Pigneux, A, Horst, H-A, Recher, C, Klimek, VM, Cortes, J, Roboz, GJ, Craig, AR, Fox, JA, Ward, R, Smith, JA, Acton, G, Mehta, C, Kantarjian, HM, and Stuart, RK. "Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study." KARGER, October 1, 2015. Link to Item
  - Perl, A, Altman, J, Cortes, J, Levis, M, Smith, C, Litzow, M, Baer, MR, Claxton, D, Erba, H, Gill, S, Goldberg, S, Jurcic, J, Larson, RA, Liu, C, Ritchie, E, Sargent, B, Schiller, G, Spira, A, Strickland, S, Tibes, R, Ustun, C, Wang, ES, Stuart, R, and Bahceci, E. "RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA." 20th Congress of European-Hematology-Association. Vienna, AUSTRIA. June 11, 2015 - June 14, 2015. FERRATA STORTI FOUNDATION, June 1, 2015. Link to Item
  - Ravandi, F, Ritchie, EK, Sayar, H, Lancet, JE, Craig, MD, Vey, N, Strickland, SA, Erba, HP, Pigneux, A, Horst, HA, Recher, C, Klimek, VM, Odenike, O, Craig, AR, Ward, R, Smith, JA, Kantarjian, HM, Stuart, RK, and Schiller, GJ. "ALLOGENEIC TRANSPLANT IN PATIENTS >= 60 YEARS OF AGE WITH FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA AFTER TREATMENT WITH VOSAROXIN OR PLACEBO PLUS CYTARABINE: RESULTS FROM VALOR." 20th Congress of European-Hematology-Association. Vienna, AUSTRIA. June 11, 2015 - June 14, 2015. FERRATA STORTI FOUNDATION, June 1, 2015. Link to Item
  - Ravandi, F, Ritchie, EK, Sayar, H, Lancet, JE, Craig, MD, Vey, N, Strickland, SA, Schiller, GJ, Jabbour, E, Erba, HP, Pigneux, A, Horst, HA, Recher, C, Klimek, VM, Cortes, J, Roboz, GJ, Craig, AR, Fox, JA, Ward, R, Smith, JA, Acton, G, Mehta, C, Kantarjian, HM, and Stuart, RK. "IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY." 20th Congress of European-Hematology-Association. Vienna, AUSTRIA. June 11, 2015 - June 14, 2015. FERRATA STORTI FOUNDATION, June 1, 2015. Link to Item
  - Nand, S, Achille, N, Othus, M, Phelan, KW, Zhang, S, Cooper, KA, Godwin, JE, Appelbaum, FR, Radich, JP, Erba, HP, and Zeleznik-Le, N. "Association between early promoter methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT0065884)." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer. Chicago, IL. May 29, 2015 - June 2, 2015.: AMER SOC CLINICAL ONCOLOGY, May 20, 2015. Link to Item
  - Schiller, GJ, Ritchie, EK, Sayar, H, Lancet, JE, Craig, MD, Vey, N, Strickland, SA, Erba, HP, Pigneux, A, Horst, H-A, Recher, C, Klimek, VM, Odenike, O, Craig, AR, Ward, R, Smith, J, Kantarjian, HM, Stuart, RK, and Ravandi, F. "Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer. Chicago, IL. May 29, 2015 - June 2, 2015.: AMER SOC CLINICAL ONCOLOGY, May 20, 2015. Link to Item
  - Steensma, D, Abedi, M, Bejar, R, Cogle, C, Foucar, K, Garcia-Manero, G, George, T, Grinblatt, D, Komrokji, R, Maciejewski, J, Pollyea, D, Roboz, G, Savona, M, Scott, B, Sekeres, M, Thompson, M, Sugrue, M, Swern, A, Nifenecker, M, and Erba, H. "249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY." : Elsevier BV, April 2015. Full Text
  - Erba, HP, Khaled, SK, and Stein, AS. "SGN-CD33A: Case Reports of Anti-Leukemic Activity and Bridge to Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML)." : Elsevier BV, February 2015. Full Text
  - Innis-Shelton, R, Salzman, D, Di Stasi, A, Lamb, LS, Gazi, M, Williams, L, Costa, LJ, Erba, H, Mineishi, S, and Saad, A. "Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience." AMER SOC HEMATOLOGY, December 6, 2014. Link to Item
  - Ravandi, F, Ritchie, E, Sayar, H, Lancet, J, Craig, MD, Vey, N, Strickland, SA, Schiller, G, Jabbour, E, Erba, HP, Pigneux, A, Horst, H-A, Recher, C, Klimek, VM, Cortes, J, Feldman, EJ, Craig, AR, Fox, JA, Ward, R, Smith, J, Acton, G, Mehta, C, Kantarjian, HM, and Stuart, RK. "Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)." 56th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2014 - December 9, 2014.: AMER SOC HEMATOLOGY, December 6, 2014. Link to Item
  - Sekeres, MA, Othus, M, List, AF, Odenike, O, Stone, RM, Gore, SD, Litzow, MR, Buckstein, R, Velasco, MR, Gaur, R, Atallah, E, Attar, E, Appelbaum, FR, and Erba, HP. "A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117." : AMER SOC HEMATOLOGY, December 6, 2014. Link to Item
  - Stein, EM, Stein, A, Walter, RB, Fathi, AT, Lancet, JE, Kovacsovics, TJ, Advani, AS, DeAngelo, DJ, O'Meara, MM, Zhao, B, Kennedy, DA, and Erba, HP. "Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML)." 56th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2014 - December 9, 2014.: AMER SOC HEMATOLOGY, December 6, 2014. Link to Item
  - Stock, W, Luger, SM, Advani, AS, Geyer, S, Harvey, RC, Mullighan, CG, Willman, CL, Malnassy, G, Parker, E, Laumann, KM, Sanford, B, Marcucci, G, Paietta, EM, Liedtke, M, Claxton, DF, Foster, MC, Appelbaum, FR, Erba, H, Litzow, MR, Tallman, MS, Stone, RM, and Larson, RA. "Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of US Intergroup Trial C10403." 56th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2014 - December 9, 2014.: AMER SOC HEMATOLOGY, December 6, 2014. Link to Item
  - Swords, RT, Savona, MR, Maris, MB, Erba, HP, Berdeja, JG, Foran, JM, Hua, Z, Faessel, HM, Dash, AB, Sedarati, F, Dezube, BJ, and Medeiros, BC. "Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial." 56th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2014 - December 9, 2014.: AMER SOC HEMATOLOGY, December 6, 2014. Link to Item
  - Walter, RB, Othus, M, Loewenberg, B, Ossenkoppele, GJ, Petersdorf, SH, Pabst, T, Vekemans, M-C, Appelbaum, FR, Erba, HP, and Estey, EH. "Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG." 56th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2014 - December 9, 2014.: AMER SOC HEMATOLOGY, December 6, 2014. Link to Item
  - Swords, RT, Savona, MR, Maris, MB, Erba, HP, Hua, Z, Faessel, H, Blakemore, SJ, Sedarati, F, Dezube, BJ, and Medeiros, BC. "FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL." 19th Congress of the European-Hematology-Association. Milan, ITALY. June 12, 2014 - June 15, 2014. FERRATA STORTI FOUNDATION, June 1, 2014. Link to Item
  - DiPersio, JF, Erba, HP, Larson, RA, Luger, SM, Mangan, KF, Tallman, MS, Brill, JM, Vuagniaux, G, Rouits, E, Zanna, C, and Sorensen, JM. "Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML)." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Steensma, DP, Abedi, M, Attar, EC, Bejar, R, Cogle, CR, Garcia-Manero, G, Grinblatt, DL, Ma, X, Maciejewski, JP, Pollyea, DA, Roboz, GJ, Savona, M, Scott, BL, Sekeres, MA, Thompson, MA, Zernovak, O, Sugrue, MM, Swern, AS, Nifenecker, M, and Erba, HP. "Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Advani, AS, Sanford, B, Luger, S, Devidas, M, Larsen, EC, Liedtke, M, Voorhees, PM, Foster, MC, Claxton, DF, Geyer, S, Parker, E, Coffan, K, Carroll, WL, Winick, NJ, Coutre, SE, Tallman, MS, Appelbaum, FR, Erba, HP, Stone, RM, Hunger, SP, Larson, RA, and Stock, W. "Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)." : AMER SOC HEMATOLOGY, November 15, 2013. Link to Item
  - DeAngelo, DJ, Erba, HP, Maris, MB, Swords, RT, Anwer, F, Altman, JK, Hua, Z, Blakemore, SJ, Faessel, H, Dezube, BJ, and Medeiros, BC. "MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study." 55th Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 7, 2013 - December 10, 2013.: AMER SOC HEMATOLOGY, November 15, 2013. Link to Item
  - Fang, M, McDonough, S, Othus, M, Zhuo, LT, Roulston, D, Erba, HP, and Appelbaum, FR. "Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing - Retrospective Review Of The SWOG Experience." 55th Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 7, 2013 - December 10, 2013.: AMER SOC HEMATOLOGY, November 15, 2013. Link to Item
  - Prebet, T, Sun, Z, Ketterling, R, Greenberg, PL, Zeidan, AM, Litzow, MR, Gabrilove, JL, Erba, HP, Paietta, E, Czader, M, Gore, SD, and Tallman, MS. "Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study." 55th Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 7, 2013 - December 10, 2013.: AMER SOC HEMATOLOGY, November 15, 2013. Link to Item
  - Advani, AS, McDonough, S, Copelan, E, Willman, CL, Mulford, DA, List, AF, Sekeres, MA, Othus, M, Erba, HP, and Appelbaum, FR. "SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML)." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. May 31, 2013 - June 4, 2013.: AMER SOC CLINICAL ONCOLOGY, May 20, 2013. Link to Item
  - Donnellan, WB, Ghosh, MG, Rangarajan, S, Jackson, B, Borate, U, Erba, HP, and Foran, JM. "Use of flow cytometry during induction chemotherapy to determine outcomes in acute myeloid leukemia." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. May 31, 2013 - June 4, 2013.: AMER SOC CLINICAL ONCOLOGY, May 20, 2013. Link to Item
  - Zeidan, A, Sun, Z, Prebet, T, Greenberg, P, Juckett, M, Smith, MR, Paietta, E, Gabrilove, JL, Erba, HP, Gore, S, and Tallman, MS. "Application of the French prognostic score (FPS) to assess overall survival (OS) in a US-based cohort of patients (pts) treated with azacitidine (Aza)." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. May 31, 2013 - June 4, 2013.: AMER SOC CLINICAL ONCOLOGY, May 20, 2013. Link to Item
  - Zeidan, A, Zhuoxin, S, Prebet, T, Greenberg, P, Juckett, M, Smith, M, Paietta, E, Gabrilove, J, Erba, H, Gore, S, and Tallman, M. "P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine." : Elsevier BV, May 2013. Full Text
  - Stone, RM, Appelbaum, FR, St, C, Erba, H, Larson, RA, Little, R, and Tallman, MS. "North American Cooperative Trials in AML." SPRINGER, February 1, 2013. Link to Item
  - Nand, S, Othus, M, Godwin, JE, Willman, CL, Norwood, T, Erba, HP, Howard, D, Coutre, SE, and Appelbaum, FR. "A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients." 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). Atlanta, GA. December 8, 2012 - December 11, 2012.: AMER SOC HEMATOLOGY, November 16, 2012. Link to Item
  - Othus, M, Kantarjian, HM, Petersdorf, S, Ravandi, F, Cortes, JE, Pierce, SA, Erba, HP, Faderl, S, Appelbaum, FR, and Estey, EH. "Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given "Intensive" Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)." 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). Atlanta, GA. December 8, 2012 - December 11, 2012.: AMER SOC HEMATOLOGY, November 16, 2012. Link to Item
  - Jain, N, Curran, E, Iyengar, NM, Diaz-Flores, E, Kunnavakkam, R, Popplewell, L, Kirschbaum, MH, Erba, HP, Green, M, Poire, X, Koval, G, Shannon, K, Atallah, EL, Dy, P, Smith, SE, Doyle, LA, Larson, RA, Stock, W, and Odenike, O. "Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML)." 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 1, 2012 - June 6, 2012.: AMER SOC CLINICAL ONCOLOGY, May 20, 2012. Link to Item
  - Nand, S, Gundacker, H, Godwin, JE, Willman, CL, Norwood, T, Erba, HP, Howard, DS, Coutre, SE, Othus, M, and Appelbaum, FR. "A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol-Report on the good-risk patients." 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 1, 2012 - June 6, 2012.: AMER SOC CLINICAL ONCOLOGY, May 20, 2012. Link to Item
  - Ravandi, F, Ritchie, EK, Sayar, H, Strickland, SA, Craig, M, Selleslag, DLD, Maertens, J, Havelange, V, Lancet, JE, Ketchum, SB, Acton, G, Mehta, CR, Silva, E, Craig, A, Fox, JA, Stuart, RK, Erba, HP, Vey, N, Schiller, GJ, and Feldman, EJ. "VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia." 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 1, 2012 - June 6, 2012.: AMER SOC CLINICAL ONCOLOGY, May 20, 2012. Link to Item
  - Pogosova-Agadjanyan, EL, Kopecky, KJ, Petersdorf, S, Erba, HP, Stone, RM, Meshinchi, S, Nevill, TJ, Radich, JP, Stenke, L, Slovak, ML, Stuart, RK, Tallman, MS, Willman, CL, Mortensen, RM, Wentz, BL, Appelbaum, FR, and Stirewalt, DL. "Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG." 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis. San Diego, CA. December 10, 2011 - December 13, 2011.: AMER SOC HEMATOLOGY, November 18, 2011. Link to Item
  - Uy, GL, Avigan, D, Cortes, JE, Becker, PS, Chen, RW, Liesveld, JL, Hewes, B, Johns, D, and Erba, HP. "Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study." 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis. San Diego, CA. December 10, 2011 - December 13, 2011.: AMER SOC HEMATOLOGY, November 18, 2011. Link to Item
  - Mehta, CR, Michelson, G, Salganik, M, Feaster, J, Allen, R, Cahill, AL, Fox, JA, Ketchum, SB, Ravandi, F, Erba, HP, Schiller, GJ, Stuart, RK, Vey, N, and Feldman, EJ. "Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia." : American Society of Clinical Oncology (ASCO), May 20, 2011. Full Text
  - Shepard, DD, Kohrt, HE, Rosenblat, TL, Jurcic, JG, Park, JH, Goldman, A, Dalal, JS, Maslak, PG, Jakubowski, AA, Klimek, V, Berman, E, Nand, S, Coutre, SE, Tallman, MS, and Erba, HP. "Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL." : American Society of Clinical Oncology (ASCO), May 20, 2011. Full Text
  - Stone, RM, Allen, SL, Pigneux, A, Stuart, RK, Wetzler, M, Rizzieri, D, Erba, HP, Damon, LE, Jang, JH, Tallman, MS, Warzocha, K, Masszi, T, Sekeres, MA, Miklos, E, Horst, H, Selleslag, DLD, Solomon, SR, Venugopal, P, Lundberg, AS, and Powell, BL. "A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE)." : American Society of Clinical Oncology (ASCO), May 20, 2011. Full Text
  - Mineishi, S, Magenau, J, Tobai, H, Pawarode, A, Peres, EM, Reddy, P, Kitko, C, Choi, S, Erba, HP, Kujawski, L, Yanik, G, Ferrara, J, and Levine, JE. "Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan x 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML." 52nd Annual Meeting of the American-Society-of-Hematology (ASH). Orlando, FL. December 4, 2010 - December 7, 2010.: AMER SOC HEMATOLOGY, November 19, 2010. Link to Item
  - Mohan, SR, Maciejewski, JP, Tejura, B, Erba, HP, Stone, RM, and Sekeres, MA. "A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML." 52nd Annual Meeting of the American-Society-of-Hematology (ASH). Orlando, FL. December 4, 2010 - December 7, 2010.: AMER SOC HEMATOLOGY, November 19, 2010. Link to Item
  - Prebet, T, Gore, SD, Sun, Z, Greenberg, PL, Juckett, M, Malick, L, Smith, MR, Paietta, E, Czader, M, Gabrilove, J, Erba, HP, and Tallman, MS. "Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905." 52nd Annual Meeting of the American-Society-of-Hematology (ASH). Orlando, FL. December 4, 2010 - December 7, 2010.: AMER SOC HEMATOLOGY, November 19, 2010. Link to Item
  - Prebet, T, Sun, Z, Ketterling, R, Hicks, G, Beach, CL, Greenberg, PL, Paietta, E, Czader, M, Gabrilove, J, Erba, HP, Tallman, MS, and Gore, SD. "A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study." 52nd Annual Meeting of the American-Society-of-Hematology (ASH). Orlando, FL. December 4, 2010 - December 7, 2010.: AMER SOC HEMATOLOGY, November 19, 2010. Link to Item
  - Swords, RT, Erba, HP, DeAngelo, DJ, Smith, PG, Pickard, MD, Dezube, BJ, Giles, FJ, and Medeiros, BC. "The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study." 52nd Annual Meeting of the American-Society-of-Hematology (ASH). Orlando, FL. December 4, 2010 - December 7, 2010.: AMER SOC HEMATOLOGY, November 19, 2010. Link to Item
  - Sekeres, M, Allen, S, Mohan, S, Lundberg, A, and Erba, H. "TREATMENT-RELATED AML AND AML EVOLVING FROM MDS: SIMILAR OUTCOMES FOLLOWING TREATMENT WITH AMONAFIDE plus CYTARABINE." 15th Annual Meeting of the European-Hematology-Association. Barcelona, SPAIN. June 10, 2010 - June 13, 2010. FERRATA STORTI FOUNDATION, June 1, 2010. Link to Item
  - Sekeres, MA, Allen, SL, Mohan, SR, Lundberg, AS, and Erba, HP. "Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine." : American Society of Clinical Oncology (ASCO), May 20, 2010. Full Text
  - Magenau, J, Pawarode, A, Buck, T, Jones, D, Kato, K, Harris, A, Frame, D, Kujawski, L, Erba, H, Peres, E, Reddy, P, Kitko, C, Choi, S, Yanik, G, Braun, T, Ferrara, J, Levine, J, and Mineishi, S. "Allogeneic haematopoietic cell transplantation with clofarabine/busulfan x 4 conditioning exhibits significant anti-leukaemic activity in non-remission AML." 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting. Vienna, AUSTRIA. March 21, 2010 - March 24, 2010. NATURE PUBLISHING GROUP, March 1, 2010. Link to Item
  - Downie, BJ, Erba, HP, Stone, RM, Rizzieri, DA, and Foran, JM. "Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy." 51st Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009. AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Erba, HP, Faderl, S, Claxton, DF, Arellano, M, Lyons, RM, Kovacsovics, TJ, Gabrilove, J, Eckert, S, Huebner, D, and Kantarjian, HM. "Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors." 51st Annual Meeting and Exposition of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009.: AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Erba, HP, O'Donnell, M, Allen, SL, Baer, MR, Powell, BL, Stone, RM, Bennett, JM, Lundberg, AS, Capizzi, RL, and Rizzieri, DA. "Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study." 51st Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009. AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Gabrilove, J, Faderl, S, Erba, HP, Claxton, DF, Arellano, M, Lyons, RM, Kovacsovics, TJ, Eckert, S, Huebner, D, and Kantarjian, HM. "Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors." 51st Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009.: AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Levis, M, Ravandi, F, Wang, ES, Baer, MR, Perl, A, Coutre, S, Erba, H, Stuart, RK, Baccarani, M, Cripe, LD, Tallman, MS, Meloni, G, Godley, LA, Langston, AA, Amadori, S, Lewis, ID, Nagler, A, Stone, R, Yee, K, Advani, A, Douer, D, Jedrzejczak, WW, Juliusson, G, Litzow, MR, Petersdorf, S, Sanz, M, Kantarjian, HM, Sato, T, Tremmel, L, Bensen-Kennedy, DM, Small, D, and Smith, BD. "Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse." 51st Annual Meeting and Exposition of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009. AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Malek, S, Ouillette, P, Wang, Y, Liu, Y, Wright, W, Roulston, D, Dressel, AL, Karp, J, Bockenstedt, P, Al-Zoubi, A, Talpaz, M, Kujawski, L, Liu, Y, Shedden, K, Shakhan, S, Li, C, Erba, HP, and Parkin, B. "Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia." 51st Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009.: AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Malek, S, Parkin, B, Ouillette, P, Kujawski, L, Erba, HP, Campagnaro, EL, Kaminski, MS, Shedden, K, and Saiya-Cork, K. "A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia." 51st Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009.: AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Odenike, O, Curran, E, Iyengar, N, Popplewell, L, Kirschbaum, M, Erba, HP, Green, M, Poire, X, Ihonor, P, Diaz-Flores, E, Shannon, K, Atallah, E, Wade, JL, Perdekamp, M, Nattam, S, Thomas, SP, Smith, SE, Doyle, LA, Rich, ES, Larson, RA, and Stock, W. "Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML)." 51st Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009.: AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Petersdorf, S, Kopecky, K, Stuart, RK, Larson, RA, Nevill, TJ, Stenke, L, Slovak, ML, Tallman, MS, Willman, CL, Erba, H, and Appelbaum, FR. "Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia." 51st Annual Meeting of the American-Society-of-Hematology. New Orleans, LA. December 5, 2009 - December 8, 2009. AMER SOC HEMATOLOGY, November 20, 2009. Link to Item
  - Erba, HP. "Prognostic factors in elderly patients with myelodysplastic syndrome or acute myeloid leukemia and the implications for treatment." June 15, 2009.
  - Lundberg, S, Chau, M, Erba, HP, Dressel, AL, Acton, G, Capizzi, RL, and Baer, MR. "AMONAFIDE (AS1413) IS UNAFFECTED BY MULTIDRUG RESISTANCE AND IS ASSOCIATED WITH A HIGH RESPONSE RATE IN PATIENTS WITH SECONDARY AML." 14th Annual Meeting of the European-Hematology-Association. Berlin, GERMANY. June 4, 2009 - June 7, 2009. FERRATA STORTI FOUNDATION, June 1, 2009. Link to Item
  - Erba, HP, Kantarjian, HM, Claxton, DF, Arellano, M, Lyons, RM, Kovacsovics, TJ, Gabrilove, J, Eckert, S, and Faderl, S. "Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s)." 45th Annual Meeting of the American-Society-of-Clinical-Oncology. Orlando, FL. May 29, 2009 - June 2, 2009. AMER SOC CLINICAL ONCOLOGY, May 20, 2009. Link to Item
  - Raza, A, Galili, N, Borthakur, G, Carter, TH, Claxton, DF, Erba, HP, DeAngelo, DJ, Berger, MS, and Schimmer, A. "A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML)." 45th Annual Meeting of the American-Society-of-Clinical-Oncology. Orlando, FL. May 29, 2009 - June 2, 2009. AMER SOC CLINICAL ONCOLOGY, May 20, 2009. Link to Item
  - Magenau, J, Pawarode, A, Buck, T, Jones, D, Kato, K, Frame, D, Kujawski, L, Erba, HP, Khaled, Y, Peres, EM, Krijanovski, OI, Reddy, P, Kitko, C, Choi, S, Yanik, G, Braun, T, Ferrara, JLM, Levine, JE, and Mineishi, S. "Conditioning with Clofarabine and Busulfan X 4 (CloBu4) For Non-Remission Hematologic Malignancies Including Aml Is Well Tolerated, Facilitates Secure Engraftment, And Exhibits Significant Anti-Tumor Activity." : Elsevier BV, February 2009. Full Text
  - Erba, HP, Kantarjian, H, Claxton, DF, Arellano, M, Lyons, RM, Kovacsovics, TJ, Gabrilove, J, Eckert, S, Abichandani, R, and Faderl, S. "Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy." 50th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2008 - December 9, 2008.: AMER SOC HEMATOLOGY, November 16, 2008. Link to Item
  - Long, J, Ouillette, P, Parkin, B, Erba, H, Wang, S, and Malek, S. "Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia." 50th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2008 - December 9, 2008. AMER SOC HEMATOLOGY, November 16, 2008. Link to Item
  - Malek, S, Ouillette, P, Wright, W, Dressel, A, Karp, J, Bockenstedt, P, Al-Zoubi, A, Talpaz, M, Kujawski, L, Shedden, K, Shakhan, S, Li, C, Erba, H, and Parkin, B. "Comprehensive Ultra High Resolution Analysis of Copy Number and Allele Status Including Novel Microdeletions Spanning NF1 in Acute Myelogenous Leukemia." 50th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2008 - December 9, 2008. AMER SOC HEMATOLOGY, November 16, 2008. Link to Item
  - Mineishi, S, Magenau, J, Pawarode, A, Buck, T, Jones, D, Kato, K, Frame, D, Kujawski, L, Erba, HP, Khaled, Y, Peres, EM, Krijanovski, OI, Reddy, P, Kitko, C, Choi, S, Yanik, GA, Braun, T, Ferrara, JLM, and Levine, JE. "Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML." 50th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA. December 6, 2008 - December 9, 2008.: AMER SOC HEMATOLOGY, November 16, 2008. Link to Item
  - Erba, H, Kantarjian, H, Claxton, D, Arellano, M, Lyons, R, Kovacsovics, T, Gabrilove, J, Eckert, S, Abichandani, R, and Faderl, S. "PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY." 13th Congress of the European-Hematology-Association. Copenhagen, DENMARK. June 12, 2008 - June 15, 2008. FERRATA STORTI FOUNDATION, June 1, 2008. Link to Item
  - Erba, HP, Kantarjian, HM, Claxton, D, Arellano, M, Lyons, R, Kovacsovics, T, Gabrilove, J, Eckert, S, Abichandani, R, and Faderl, S. "Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy." : American Society of Clinical Oncology (ASCO), May 20, 2008. Full Text
  - Lundberg, AS, Baer, MR, Chau, M, Erba, HP, Dressel, AL, Ajami, AM, and Capizzi, RL. "Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy." : American Society of Clinical Oncology (ASCO), May 20, 2008. Full Text
  - Erba, HP, Kopecky, KJ, Kirschbaum, MH, Tallman, MS, Larson, RA, Willman, CL, Slovak, ML, Gundacker, HM, and Appelbaum, FR. "Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American intergroup study S0432." SPRINGER, February 1, 2008. Link to Item
  - Erba, HP, Kopecky, KJ, Kirschbaum, MH, Tallman, MS, Larson, RA, Willman, CL, Slovak, ML, Gundacker, HM, and Appelbaum, FR. "Phase II studies of different schedules and doses of the farnesyl transferase inhibitor tipifarnib (R115777, zarnestra, NSC-702818) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): A north American intergroup study (S0432)." 49th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA. December 8, 2007 - December 11, 2007.: AMER SOC HEMATOLOGY, November 16, 2007. Link to Item
  - Malek, SN, Erba, H, Mark, KS, Kerby, S, and Peter, O. "Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14 with differential expression of LATS2." 49th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA. December 8, 2007 - December 11, 2007. AMER SOC HEMATOLOGY, November 16, 2007. Link to Item
  - Malek, SN, Ouillette, P, Erba, H, Saddler, C, Jakubowiak, A, Kaminski, M, Shedden, K, and Kujawski, L. "Genomic complexity identifies patients with agressive chronic lymphocytic leukemia." 49th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA. December 8, 2007 - December 11, 2007. AMER SOC HEMATOLOGY, November 16, 2007. Link to Item
  - Malek, SN, Ouillette, P, Kujawski, L, Shangary, S, Talpaz, M, Kaminski, M, Erba, H, Shedden, K, and Wang, S. "Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia." 49th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA. December 8, 2007 - December 11, 2007. AMER SOC HEMATOLOGY, November 16, 2007. Link to Item
  - Sekeres, MA, Kalaycio, ME, Erba, HP, Sobecks, R, Advani, A, Chan, J, and Maciejewski, JP. "P155 Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS." : Elsevier BV, May 2007. Full Text
  - Malek, SN, Kujawski, LA, Erba, HP, Kaminski, MS, Jakubowiak, A, Dressel, A, Saddler, CM, Shedden, KA, and Ouillette, PD. "Genomic profiling of chronic lymphocytic leukemia identifies novel genetic subtypes." 48th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 9, 2006 - December 12, 2006.: AMER SOC HEMATOLOGY, November 16, 2006. Link to Item
  - Norwood, TH, Gundacker, HM, Slovak, ML, Erba, HP, and Appelbaum, FR. "Changes in the pattern of cytogenetic aberrations with advancing age in acute myeloid (Non-APL) leukemia: A Southwest Oncology study (S9007)." 48th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 9, 2006 - December 12, 2006.: AMER SOC HEMATOLOGY, November 16, 2006. Link to Item
  - Sekeres, MA, Maciejewski, JP, Erba, HP, Sobecks, R, Advani, A, Nichols, J, Chan, J, and Kalaycio, M. "A phase II trial of combination therapy with arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) arising from MDS." 48th Annual Meeting of the American-Society-of-Hematology. Orlando, FL. December 9, 2006 - December 12, 2006.: AMER SOC HEMATOLOGY, November 16, 2006. Link to Item
  - Kujawski, LA, Ryan, I, Griffith, K, and Erba, HP. "Combination of datmorubicin and cytarabine chemotherapy with gemtuzumab ozogamicin as initial therapy for elderly patients with previously untreated acute myeloid leukemia." 47th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA. December 10, 2005 - December 13, 2005.: AMER SOC HEMATOLOGY, November 16, 2005. Link to Item
  - Levis, M, Smith, BD, Beran, M, Baer, MR, Erba, HP, Cripe, L, Coutre, S, Advani, A, Perl, A, Devetten, M, Stuart, R, Tallman, MS, Brown, P, Tremmel, L, and Small, D. "A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition." 47th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA. December 10, 2005 - December 13, 2005.: AMER SOC HEMATOLOGY, November 16, 2005. Link to Item
  - Collins, CD, DePestel, DD, Stuntebeck, ER, Shehab, N, Erba, HP, and Stevenson, JG. "PIN5 COST ANALYSIS OFA FEBRILE NEUTROPENIA ALGORITHM WITH RESPECT TO EMPIRICAL ANTIFUNGAL THERAPY IN ADULT HEMATOLOGY/ONCOLOGY PATIENTS." : Elsevier BV, May 2005. Full Text
  - Kujawski, LA, Gartner, EM, Ryan, I, Griffith, K, and Erba, HP. "Gemtuzumab ozogamicin (Mylotarg (R)) as primary induction therapy for elderly patients with acute myeloid leukemia: A phase II trial." 46th Annual Meeting of the American-Society-of-Hematology. San Diego, CA. December 4, 2004 - December 7, 2004.: AMER SOC HEMATOLOGY, November 16, 2004. Link to Item
  - Erba, HP, Stadtmauer, EA, Larson, RA, Sievers, EL, Esrey, EH, Lowenberg, B, Sherman, ML, Herbertson, RK, and Appelbaum, FR. "Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation." 45th Annual Meeting of the American-Society-of-Hematology. SAN DIEGO, CALIFORNIA. December 6, 2003 - December 9, 2003.: AMER SOC HEMATOLOGY, November 16, 2003. Link to Item
  - Kilgore, S, Erba, H, Valdez, R, Finn, W, Schnitzer, B, and Ross, C. "Mylotarg (gemtuzumab ozogamicin; CMA-676) in AML: Predictive variables and response to treatment." 92nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology. WASHINGTON, D.C. March 22, 2003 - March 28, 2003. LIPPINCOTT WILLIAMS & WILKINS, January 1, 2003. Link to Item
  - Kilgore, S, Erba, H, Valdez, R, Finn, W, Schnitzer, B, and Ross, C. "Mylotarg(Gemtuzumab Ozogamicin;CMA-676) in AML: Predictive variables and response to treatment." 92nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology. WASHINGTON, D.C. March 22, 2003 - March 28, 2003. LIPPINCOTT WILLIAMS & WILKINS, January 1, 2003. Link to Item
  - Erba, HP, Stadtmauer, EA, Larson, RA, Sievers, EL, Estey, EH, Lowenberg, B, Leopold, LH, Berger, MS, Herbertson, R, and Appelbaum, FR. "Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin." 44th Annual Meeting of the American-Society-of-Hematology. PHILADELPHIA, PENNSYLVANIA. December 6, 2002 - December 10, 2002.: AMER SOC HEMATOLOGY, November 16, 2002. Link to Item
  - Raza, A, Fenaux, P, Erba, H, Mandelli, F, Schiller, G, Larson, R, Denzlinger, C, Greenberg, P, Muus, P, Gotlib, J, Bennett, J, Leopold, L, Lejeune, C, Richie, M, and Berger, M. "Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome." 44th Annual Meeting of the American-Society-of-Hematology. PHILADELPHIA, PENNSYLVANIA. December 6, 2002 - December 10, 2002. AMER SOC HEMATOLOGY, November 16, 2002. Link to Item
  - Sievers, EL, Larson, RA, Estey, E, Lowenberg, B, Erba, HP, Gramatzki, M, List, A, Sierra, J, Stadtmauer, EA, Tarantolo, S, Berger, MS, Leopold, LH, Eten, C, Munteanu, M, Stone, A, Bernstein, ID, and Appelbaum, FR. "Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation." : AMER SOC HEMATOLOGY, November 16, 2000. Link to Item
  - Sievers, EL, Larson, RA, Estey, E, Stadtmauer, EA, Erba, HP, Roy, DCC, Tarantolo, L, Spielberger, R, Berger, MS, Eten, C, Manley, L, Stone, A, Bernstein, I, and Appelbaum, FR. "Efficacy and safety of CMA-676 in patients with AML in first relapse." : AMER SOC HEMATOLOGY, November 15, 1999. Link to Item
  - Alereidi, F, Terebelo, H, Erba, H, and Ross, C. "Transformation of chronic lymphocytic leukemia (CLL) to Hodgkin's disease (ZED) - A treatable entity." W B SAUNDERS CO, November 15, 1998. Link to Item
  - "NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network." November 1998.
  - Aster, J, Pear, W, Hasserjian, R, Erba, H, Davi, F, Luo, B, Scott, M, Baltimore, D, and Sklar, J. "Functional analysis of the TAN-1 gene, a human homolog of Drosophila notch." January 1994. Full Text
  - KEDES, L, MINTY, A, WADE, R, GUNNING, P, HARDEMAN, E, BLAU, H, BENTONVOSMAN, P, BOXER, L, ERBA, H, FELDMAN, D, GAHLMANN, R, MIWA, T, MUSCAT, G, and TAYLOR, A. "MULTILEVEL REGULATION OF GENE-EXPRESSION IN HUMAN MYOGENESIS - DISSOCIATION OF FACTORS RESPONSIBLE FOR MODULATION AND ACTIVATION AND EVIDENCE FOR NON-COORDINATE EXPRESSION." WILEY-LISS, January 1, 1986. Link to Item
Teaching & Mentoring
Advising & Mentoring
- I am available as an advisor or mentor for medical students, residents, fellows and junior faculty. Specifically, I am happy to provide advice regarding a career in academic medicine as a clinical investigator. I am interested in mentoring trainees and junior faculty in clinical investigation in leukemias, myelodysplastic syndromes and myeloproliferative neoplasms.
Scholarly, Clinical, & Service Activities
Service to the Profession
Academic & Administrative Activities
- Director, Leukemia Program
  Director, Phase I Development in Hematologic Malignancies
Clinical Activities
- Clinic hours:
  
  Monday, 12 p.m. to 5 p.m.
  Wednesday, 12 p.m. to 5 p.m.
  Thursday, 8 a.m. to 5 p.m.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Medical Licensure

Leadership & Clinical Positions at Duke

Academic Positions Outside Duke

Awards & Honors

Subject Headings

Global Scholarship

Research

Teaching

Selected Grants

Selected Publications

Academic Articles

Book Sections

Conference Papers

Advising & Mentoring

Service to the Profession

Academic & Administrative Activities

Clinical Activities